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Abstract 
Rheumatic heart disease (RHD) is the major cause of acquired heart disease and death for 
children and young adults in developing countries.  Poverty and social disadvantage are 
thought to influence the clinical outcomes in RHD patients. Guided by the health lifestyle 
theory, this study assessed the relationship between socioeconomic status and clinical 
outcomes (heart failure events and mortality) in patients with RHD. It also examined how 
adherence to penicillin prophylaxis mediates the effect of socioeconomic status (SES) on 
clinical outcomes. Using the Nigerian database of the REMEDY study, this study was 
conducted with 243 participants using Poisson regression and logistic regression models. 
There was statistically significant association between SES and heart failure events 
(OR=4.77, 95% CI=1.07-21.32, p=0.04). There was no significant association seen 
between SES and mortality. Penicillin adherence was not a significant mediatory variable 
in the relationship between SES and heart failure event and between SES and mortality. 
These findings are consistent with studies showing low SES is a potential factor for 
increased risk of recurrent heart failure events in RHD patients. It is however at variance 
with studies that showed an increased risk of heart failure and mortality in patients with 
poor adherence to penicillin prophylaxis.  A positive social change implication might be 
the need for physicians treating symptomatic patients with RHD to develop specific 
strategies for patients from lower SES in order to reduce the recurrence of heart failure. 
Future studies incorporating a composite measure of SES especially that using income as 
proxy is needed to further improve our understanding of the role of SES in clinical 
outcomes. 
 
 
  
Socioeconomic Status, Benzathine Penicillin Prophylaxis, and Clinical Outcomes in 
Patients With Rheumatic Heart Disease  
 
by 
 
Christopher Sabo Yilgwan 
 
MBBS, University of Jos, 2003 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Philosophy 
Public Health 
 
 
Walden University 
October 2020 
 
 
 
 
i 
 
Table of Contents  
List of Tables .......................................................................................................................v 
List of Figures .................................................................................................................... vi 
Chapter 1: Introduction to the Study ....................................................................................1 
Background ..............................................................................................................2 
Problem Statement ...................................................................................................4 
Nature of the  Study .................................................................................................6 
Purpose of the Study ................................................................................................7 
Research Questions and Hypotheses .......................................................................7 
Theoretical Base of the Study ..................................................................................9 
Operational Definitions ..........................................................................................10 
Assumptions ...........................................................................................................11 
Scope and Delimitations ........................................................................................12 
Limitations .............................................................................................................12 
 Significance of the Study ......................................................................................13 
 Summary ...............................................................................................................14 
Chapter 2: Literature Review .............................................................................................16 
 Literature Search Strategy.....................................................................................16 
 Theoretical Foundation .........................................................................................18 
Adherence as a Health Behavior ............................................................................21 
 Conceptual Framework .........................................................................................23 
 Rheumatic Heart Disease ......................................................................................23 
 
ii 
 
Epidemiology of Rheumatic Heart Disease ...........................................................24 
 Aetiopathogenesis of Rheumatic Heart Disease ...................................................24 
Predisposing Factors to Rheumatic Heart Disease ................................................26 
Treatment Patterns for Rheumatic Heart Disease ..............................................................30 
Prevention Strategy for Rheumatic Heart Disease .................................................32 
Role of School Based Echocardiography screening in RHD Prevention ..............33 
Penicillin Secondary Prophylaxis ..........................................................................34 
Clinical Outcomes in Rheumatic Heart Disease ....................................................36 
Socioeconomic Status and Clinical Outcomes in RHD .........................................37 
Socioeconomic Status and Benzathine Penicillin Adherence in RHD ..................38 
Adherence and Clinical Outcomes in Rheumatic Heart Disease ...........................39 
 Adherence as the Mediating Pathway ...................................................................39 
Summary and Conclusions ....................................................................................41 
Chapter 3: Research Method ..............................................................................................42 
 Research Design and Approach ............................................................................43 
 Data Sources .........................................................................................................45 
 Study setting and Population ................................................................................48 
 Power Calculations ...............................................................................................49 
 Data Collection Procedure ....................................................................................51 
 Definition of Variable ...........................................................................................52 
         Independent Variable ....................................................................................52 
         Dependent Variables .....................................................................................54 
 
iii 
 
 Analyses ................................................................................................................56 
        Handling Missing Data ..................................................................................56 
        Descriptive Analysis ......................................................................................57 
        Analyses Method Addressing each Research Question .................................57 
 Threats to Validity ................................................................................................61 
 Ethical Considerations ..........................................................................................62 
Summary…………………………………………………………………………63 
Chapter 4: Results ……………………………………………………………………….64 
Introduction and Research Questions……..……………………………………..64 
 Data collection…………………………………………………………………...65 
 Descriptive Statistics…………………………………………………………….66 
 Research Question 1……………………………………………………………..69 
 Research Question 2……………………………………………………………..72 
Research Question 3……………………………………………………………..73 
Research Question 4……………………………………………………………..76 
 Summary…………………………………………………………………………78 
Chapter 5:………………………………………………………………………………...79 
 Introduction………..……………………………………………………………..79 
Impact of Key Variables on Multiple Outcomes in RHD …...…………………..87 
Interpretation of Findings……………………………… …...…………………..89 
Limitations……………………………………………………………………….91 
Implications for Social Change…………………………………………………..92 
 
iv 
 
Recommendations………………………………………………………………..93 
Conclusions………………………………………………………………………94 
References………………………………………………………………………..96 
 
 
 
  
 
 
v 
 
List of Tables 
Table 1. Showing Oyedeji Socioeconomic Classification Scheme .................................. 54 
Table 2.  Demographic and Clinical Characteristics of 183 Subjects with RHD by SES  
    grouping……………………………………………………………………….67 
Table 3.  Comparison of Anthropometric and Echocardiographic Parameters at Baseline  
    by SES grouping……………………………………………………………....68 
Table 4. Comparison of Number of Persons Ever Had Heart Failure by 
   SES grouping………………………………………………………………….69 
Table 5. Comparison of Mean Heart Failure Events by SES grouping……………….…69 
Table 6. Model Goodness of Fit……………………………………………...………….71 
Table 7. Poisson Regression Analysis of Heart Failure Events on SES Group…………72 
Table 8. Logistic Regression Model Coefficients of SES with Mortality……………….73 
Table 9. Poisson Regression Model Coefficients of SES on Heart Failure with Adherence  
   as a Mediator…………………………………………………………………..75 
Table 10. Logistic Regression Model Coefficients of SES with Mortality with  
   Adherence as a Mediator………………………………………………………77 
 
 
 
 
  
 
vi 
 
List of Figures 
Figure 1. Showing cases needed for Research Questions  .................................................50 
 
1 
 
Chapter 1: Introduction to the Study  
 Rheumatic heart disease (RHD) a chronic sequel of acute rheumatic fever is a 
neglected public health problem prevalent among children and young adult in developing 
countries including Nigeria (Watson et al., 2017). Global estimates suggest about 33.4 
million people currently live with RHD with a further 400,000 new cases reported 
annually (Watkins et al., 2017). In addition, about 319,400 individuals were estimated to 
have died from RHD in 2015, while about 400,000 new cases were diagnosed annually 
(Watson et al., 2017) 
RHD is associated with huge public health burden especially in developing 
countries (Watkins et al., 2017). Available reports show that it is the most common cause 
of cardiovascular disease (CVD) in young people aged 25 years or below, the majority of 
whom live in Africa, the South Pacific, Middle East, Central and South Asia with 
associated high mortality and high disability-adjusted life years (DALYs). (Remenyi et 
al., 2013; Watkins et al., 2016). Most children and young people with chronic RHD in 
these developing countries present late or with severe disease needing surgical 
intervention costing millions of dollars annually in health budgets (Watkins et al., 2017; 
Zühlke et al., 2016). Current estimates suggest an annual spending in excess of 10 billion 
dollars on surgical and other treatment for chronic RHD (Remenyi et al., 2013; Watkins 
et al., 2016).  Most of this spending occurs outside the country of origin of the affected 
individuals leading to a needless capital flight (Remenyi et al., 2013; Watkins et al., 
2016). Surgery for RHD in most cases is palliative thus underscoring the need to increase 
efforts at prevention initiatives especially benzathine penicillin secondary prophylaxis, a 
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management tool demonstrated to improve clinical outcomes for patients with RHD 
(Remenyi et al., 2013; Watkins et al., 2016). 
In this chapter, I discuss the background of RHD and adherence to antibiotic 
therapy and a gap in knowledge addressed. The research problem, study purpose, and 
research questions are stated, and the theoretical basis for the study is introduced. In this 
chapter, I also discuss the significance of this study, research design, assumptions, and 
study limitations. 
Background 
RHD is a disease usually associated with social disadvantage that commonly 
occur in children aged 5-15 years and young adults between the age of 20-30 years 
(Carapetis & Zuhlke 2011). Poor hygiene, overcrowding, and poor ventilation 
predisposes the individual to the acquisition of group A beta hemolytic streptococcal 
(GABHS) pharyngitis, the original harbinger of acute rheumatic fever (ARF) which is the 
precursor of RHD (Carapetis & Zuhlke 2011; Watkins et al., 2017). The 2017 global 
burden of disease estimated age-standardized prevalence of rheumatic heart was 444 
cases per 100,000 population for countries with an endemic pattern and 3.4 cases per 
100,000 population for countries with a nonendemic pattern (Carapetis & Zuhlke 2011; 
Watkins et al., 2017). From available reports globally, the average age at first diagnosis 
of acute rheumatic fever occurs in children 10-14 years (Carapetis & Zuhlke 2011; 
Watkins et al., 2017). In addition, death from RHD usually occurs in the second or third 
decade of life. Seeing that death from RHD is uncommon among children between 5 and 
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9 years of age, there could be a risk of serious underestimation of the endemicity of RHD 
globally (Watkins et al., 2017).   
Typically, RHD progression from initial insult of acute rheumatic fever to 
symptomatic heart failure and in some cases death from the diseases and its related 
complications may span a period of about 10 years (Watkins et al., 2017).  Heart failure 
is said to be the most common sequel of RHD with an estimate 295,300 cases (95% 
uncertainty interval, 194,100 to 401,400) of mild heart failure, 243,700 cases (95% 
uncertainty interval, 176,600 to 320,900) of moderate heart failure, and 663,000 cases 
(95% uncertainty interval, 566,800 to 763,900) of severe heart failure, which represents 
an 88% increase in the number of cases overall (Watkins et al., 2017). 
Patterns of mortality due to rheumatic heart disease varied significantly according 
to world health region in 2015 (Watkins et al., 2017). While global age-standardized 
mortality from rheumatic heart disease decreased from 9.2 deaths per 100,000 population 
(95% uncertainty interval, 8.7 to 9.7) in 1990 to 4.8 deaths per 100,000 population (95% 
uncertainty interval, 4.4 to 5.1) in 2015, a decrease of 47.8% (95% uncertainty interval, 
44.7 to 50.9), an estimated 77% and 82% of the deaths in 1990 and 2015, respectively, 
occurred in countries such as India and sub-Saharan Africa where the diseases is endemic 
(Watkins et al., 2017).  
The goal for treatment of RHD is to prevent heart failure and recurrent ARF 
where possible and allow for good clinical and functional outcomes for patients living 
with this chronic disease (Remond et al., 2016; Yacoub et al., 2016). While surgical 
management limits disability by improving cardiac function, it comes with the chronic 
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need for warfarin therapy and the need for INR measurement for life as a result of the 
mechanical prosthesis inserted to replace the damaged heart valve (Cannon et al., 2017; 
Watkins et al., 2017; Zühlke et al., 2016). Benzathine penicillin prophylaxis, a once 
monthly or 3 weekly intramuscular injection has recently been shown to improve 
outcome for RHD patients by reducing the frequency of ARF recurrences and heart 
failure thus improving the overall outlook for the patient (Cannon et al., 2017; Watkins et 
al., 2017; Zühlke et al., 2016). Since deaths from RHD is mainly from heart failure and 
recurrent ARF, improve uptake of benzathine penicillin will in turn reduce the death rates 
as such improve the clinical outcome for these patients living with RHD (Cannon et al., 
2017; Watkins et al., 2017; Zühlke et al., 2016). Seeing that SES disparities impact on 
uptake of health interventions underscores the need for the measurement of disparities 
and clinical outcomes in RHD management. Achieving the best possible outcomes for all 
patients living with RHD would, therefore, include the measurement of outcomes by 
SES. (Cannon et al., 2017; Watkins et al., 2017; Zühlke et al., 2016) 
Problem Statement 
Even though RHD is associated with social disadvantage as well as low 
socioeconomic status, not many studies have looked at the role of SES in predicting 
clinical outcome for patients with RHD (Watkins et al., 2017; Weinberg et al., 2016; 
Zuhlke et al., 2016).  In a multicenter study evaluating 3343 patients with RHD across 12 
African countries, Zuhlke et al. (2016) found India and Yemen reported poorer outcome 
for patients living in low income World Bank category countries. Patients from low 
income countries had a mortality rate of 20.8% compared with those from the lower 
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middle income and upper middle-income groups, who had a mortality rate of 16.55 and 
12.5% respectively (p < 0.001) (Zühlke et al., 2016). In the same vein, new episodes of 
congestive heart failure occurred in 9% of the patients from the low-income group 
compared with those of the lower middle-income group and upper middle income who 
had rates of 6.7% and 6.1% respectively (p = 0.006) (Zühlke et al., 2016). Similarly, 
Okello et al. (2017) in a study of RHD patients in Uganda aged 5-60 years, reported a 
mortality rate of 17.5%.  Benzathine penicillin adherence rate less than 80% was noted in 
that study to significantly increase mortality rates (31% vs 9%, log rank, p < 0.001) 
(Okello et al., 2017). Antibiotic prophylaxis using penicillin has been demonstrated to 
improve the outcome for people with RHD when started early in the course of the disease 
(Remond et al., 2016; Yacoub et al., 2016). Complications like infective endocarditis, 
atrial arrhythmias, incident heart failure, stroke and even deaths have been shown to be 
more prevalent in children and young adults with severe RHD (Cannon et al., 2017; 
Watkins et al., 2017; Zühlke et al., 2016). The success of the secondary prophylaxis is 
thus hinged on the degree of adherence to the penicillin prophylaxis instituted (Cannon et 
al., 2017; Yacoub et al., 2016; Zühlke et al., 2016). No study has evaluated outcomes or 
role of BZP for patients with RHD in Nigeria even though RHD still remains a 
significant health problem in Nigeria (Watkins et al., 2017).  
In Africa, several factors have been associated with poor adherence to penicillin 
secondary prophylaxis (Watkins et al., 2017; Zühlke et al., 2016). Poverty, illiteracy, and 
access to care are some factors that have been implicated (Watkinset al., 2017; Yacoub et 
al., 2016; Zühlke et al., 2016). However, not much is known about the influence of 
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socioeconomic status and antibiotic adherence on the clinical outcomes of RHD (Cannon 
et al., 2017; Yacoub et al., 2016; Zühlke et al., 2016).  
Nature of the Study 
This study utilized a retrospective cohort design to quantitatively analyze a 
secondary data set of 243 Nigerian patients with RHD that were recruited and followed 
up over a 2-year period as part of the rheumatic heart disease global registry (REMEDY) 
study conducted across 12 African countries, Yemen and India (Karthikeyan et al., 2012; 
Zuhlke et al., 2014). To address the question of the potential influence of SES on clinical 
outcomes (heart failure and mortality rates) for these patients with RHD, this research 
used a secondary data prospectively collected from a cohort of 243 RHD patients living 
in 5 sites spread across the northern, central and southern parts of Nigeria. The patients 
enrolled in that study were evaluated and managed according to standard practices 
followed at each participating site using standard operating procedures domesticated at 
each site (Karthikeyan et al., 2012; Zuhlke et al., 2014). The patients were enrolled from 
5 sites spread across the north (Aminu Kano Teaching Hospital, Kano), central (Jos 
University teaching Hospital, Jos and University of Abuja Teaching Hospital, 
Gwagwalada) and southern parts of the country (University College Hospital, Ibadan and 
Federal Medical Center, Abeokuta). Demographic data, clinical findings, and details of 
electrocardiographic and echocardiographic findings on each patient were recorded in the 
registry case report forms at research sites at baselines of 12 months and 24 months 
(Karthikeyan et al., 2012; Zuhlke et al., 2014). This information was then transmitted and 
stored at the University of Cape Town, Department of Medicine Project Coordinating 
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Office (Karthikeyan et al., 2012; Zuhlke et al., 2014). The independent variable was SES 
while the dependent variables were mortality and heart failure. Adherence to benzathine 
penicillin was the mediator variable studied. 
Purpose of the Study 
The purpose of this study was to assess the relationship between individual level 
SES and clinical outcomes (incident heart failure rate and mortality rate) in patients with 
rheumatic heart disease (RHD). Secondly, it also examined how adherence to benzathine 
penicillin prophylaxis mediates the effect of socioeconomic status on clinical outcomes 
(heart failure and mortality rate) for these patients with RHD.  The patients recruited 
were categorized into two groups based on their SES as classified using the Oyedeji 
system of SES classification (Oyedeji et al., 1985). One cohort (Cohort 1) contained 
patients with low SES while the second (Cohort 2) contained patients with middle to 
higher SES.  
Socioeconomic status was the independent variable while clinical outcomes (heart 
failure and mortality) were the dependent variables. Benzathine penicillin adherence was 
the mediator variable.  
Research Questions 
Research Question 1 (RQ1). Does the number of heart failure events differ 
between RHD patients of low SES and RHD patients of higher SES? 
Null hypothesis (H01): There is no difference in number of heart failure events 
between RHD patients of low SES and RHD patients of higher SES. 
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Alternate hypothesis (Ha1): There is a difference in number of heart failure events 
between RHD patients of low SES and RHD patients of higher SES. 
Research Question 2 (RQ2): Does the mortality rates differ between RHD patients 
of low SES and RHD patients of higher SES? 
Null hypothesis (H02): There is no difference in mortality rates between RHD 
patients of low SES and RHD patients of higher SES. 
Alternate hypothesis (Ha2): There is a difference in mortality rates between RHD 
patients of low SES and RHD patients of higher SES. 
Research Question 3 (RQ3): Is there a significant difference in number of heart 
failure events between RHD patients of low SES and RHD patients of Higher SES when 
adjusting for the effect of benzathine penicillin prophylaxis adherence? 
Null hypothesis (H03): There is no significant difference in number of heart 
failure events between RHD patients of low SES and RHD patients of Higher SES after 
adjusting for the effect of benzathine penicillin prophylaxis adherence rates. 
Alternate hypothesis (Ha3): There is a significant difference in number of heart 
failure events between RHD patients of low SES and RHD patients of Higher SES after 
adjusting for the effect of benzathine penicillin prophylaxis adherence rates. 
Research Question 4 (RQ4): Is there a significant difference in mortality rates 
between RHD patients of low SES and RHD patients of Higher SES when adjusting for 
the effect of benzathine penicillin prophylaxis adherence? 
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Null hypothesis (H04): There is no significant difference in mortality rates 
between RHD patients of low SES and RHD patients of Higher SES after adjusting for 
the effect of benzathine penicillin prophylaxis adherence rates. 
Alternate hypothesis (Ha4): There is a significant difference in mortality rates 
between RHD patients of low SES and RHD patients of Higher SES after adjusting for 
the effect of benzathine penicillin prophylaxis adherence rates. 
Theoretical Basis of the Study 
The conceptual model for this research was derived from the health lifestyle 
framework, the theory, which was formulated by Cockerham in 2005 places emphasis on 
how structural variables such as socioeconomic status, age, gender, and race/ethnicity, 
social networks and living conditions provide the social context for socialization and 
experience that ultimately determine lifestyle dispositions and practices (Cockerham 
2005). This theory proposes that class circumstances SES may play an important role in 
determining how individuals in a community make health decisions and choices 
(Cockerham 2005). These choices may thus play an important role for both adherence 
and clinical outcomes in patients with RHD (Cockerham 2005; Glanz, Rimer, & Lewis 
2002). The correlation between SES and clinical outcomes has been previously 
established for children with RHD (Okello et al., 2013; Zuhlke et al., 2014). Although a 
correlation between SES and treatment adherence has been reported in several chronic 
diseases such as asthma, this has not been conclusively established in RHD (Apter et al. 
1998; Dean, Walters, & Hall 2010). The health lifestyle theory thus offered an 
opportunity to understand how class circumstances such as socioeconomic status 
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influences patients’ choices and decision (agency) on adhering to the monthly penicillin 
injection (adherence) a health behavior necessary for improving the clinical outcome for 
the particular patient (Cockerham 2005).  
Operational Definitions 
Acute rheumatic fever (ARF): an abnormal immune response leading to an 
inflammatory disease that affects the endothelial lining of the joints, skin, brain and heart 
following group A beta Hemolytic streptococcal pharyngitis.  
Adherence to treatment regimen: Adherence refers to the extent to which an 
individual’s behavior coincides with medical or health advice (Modi et al., 2012). 
Congestive heart failure: Inability of the heart to pump blood to the body despite a 
normal filling pressure. 
Group A beta hemolytic streptococci (GABHS) pharyngitis: A bacterial infection 
of the throat and surrounding tissues commonly seen in children aged 5-15 years and young 
adults less than 30 years of age. 
Mortality rate: Mortality is derived from the Latin word ‘mortalitas’ and refers to 
the state of being subject to death.  Mortality rate is thus a measure of the number of deaths 
due to a specific cause in a particular population per unit of time (Gordis 2013).  
Rheumatic heart disease (RHD): A chronic sequel of ARF that commonly involve 
the mitral valvular structures with resulting incompetence and backward leakage of blood 
into the left atrium. 
Socioeconomic status: This is a complex concept that defines an individual’s 
socioeconomic position in the society. Inherent in this concept is the reference to 
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economic resources such as earnings, income, and wealth, social resources such as social 
networks and connections to community resources, education and occupation. In the 
context of this study, occupation and educational attainment were used as a proxy for 
SES because of its intricate relationship to access to care and adherence to drug treatment 
(Sewell & Velayos, 2013). 
Assumptions 
In this current study of SES, adherence behavior, and clinical outcomes (death or 
mortality and heart failure events), my approach is formed by a postpositivist worldview 
which posits that outcomes or effects are determined by causes (Creswel 2009). As a 
result, being a reductionist, I assumed that concepts can be reduced to small, discrete sets 
of testable ideas, and that empirical testing and measurement can inform our knowledge 
of human behavior. Thus, the conceptual model chosen for this study places adherence to 
benzathine penicillin secondary prophylaxis regimens in the pathway between SES and 
Clinical outcomes (death, heart failure). According to the Health lifestyle theory, class 
circumstances (SES) may play an important role in determining how individuals in a 
community make health decisions and choices (Cockerham 2005). These choices may 
thus play an important role for both adherence and clinical outcomes in patients with 
RHD (Cockerham 2005; Cockerham 2013) 
In this study, I assumed that SES leads to differences in clinical outcomes as 
opposed to poor clinical status leading to differences in SES. I also assumed that patients 
with greater disease severity or activity will more likely be adherent to BZP secondary 
prophylaxis compared with patients whose disease is well controlled. Finally, I assumed 
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that low SES status negatively impacts adherence and poor adherence to BZP prophylaxis 
will worsen clinical outcomes by increasing death rates and/or heart failure recurrences in 
patients treated for RHD. These assumptions will be necessary to empirically test the 
health lifestyle model of health disparities. 
Scope and Delimitations 
Socioeconomic disparities in RHD have been observed in both adult and pediatric 
populations (Watkins et al., 2017). The scope of this study was limited to symptomatic 
patients presenting in the hospital; asymptomatic patients identified through screening 
were excluded. Adherence behaviors in symptomatic patients may be influenced by 
disease severity, access to care and SES therefore, the results of this study may not be 
applicable to asymptomatic RHD patients. 
Limitations 
I used secondary data from a disease registry to answer my research questions.  
While disease registry provides a ready source of patient data for research, there are 
inherent limitations to the use of this secondary source of data for research purposes (Yim 
et al., 2017). First, the measurement of constructs is limited to data elements available in 
the registry (e.g., a provider assessment of adherence to treatment regimen) and this may 
affect the validity of the measures for adherence. This limitation was addressed in the 
REMEDY study by using multiple sources of information (physician records and patient 
monthly injection book records) in evaluating adherence to benzathine penicillin 
secondary prophylaxis.  
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Significance of the Study 
The intent of this study was to bridge the gap in understanding the role of 
individual level socioeconomic status on clinical outcomes for persons with rheumatic 
heart disease. In addition, it was aimed at evaluating the possible mediatory role of 
benzathine penicillin prophylaxis adherence on the relationship between SES and clinical 
outcomes for these patients with RHD. The previously published report on this data had 
demonstrated a significant relationship between country level socioeconomic status and 
clinical outcomes in RHD patients (Zuhlke et al., 2015). Individual level SES was not 
investigated (Zuhlke et al., 2015). Access to care and by extension drug adherence are 
more readily affected by the individual’s economic status rather than the group economic 
level (Yim et al., 2017). Since adherence is an individual health behavior (though 
potentially influenced by group characteristics), it is easier to relate and thus examine the 
effect of BZP adherence on health outcomes with individual level SES. The results of this 
study add to the knowledge on the influence of socioeconomic status and adherence to 
benzathine penicillin prophylaxis on clinical outcomes (heart failure and death) in 
patients with RHD. It also adds to the knowledge on the mechanism through which 
benzathine penicillin adherence, (a management tool shown to impact the course and 
hence outcomes of RHD) mediate the relationship between socioeconomic status and 
clinical outcomes in patients with RHD. The findings here will thus help to improve the 
ways in which clinicians address the problem of benzathine penicillin secondary 
prophylaxis for patients with RHD especially those whose adherence problem may stem 
from poverty and its related factors thereby improving the clinical outcomes for them. 
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Summary 
RHD is the major cause of acquired heart disease and death from heart disease in 
children and young adult in most parts of the developing world especially sub-Saharan 
Africa. Currently, RHD has virally been eradicated in the developed countries such as the 
US and UK except for occasional flares among immigrant populations.  
Evidence shows that SES, adherence to drug therapy especially benzathine 
penicillin secondary prophylaxis are important factors in determining outcome for 
patients with RHD.  The health lifestyle theory can potentially explain the role of SES 
and adherence to benzathine penicillin secondary prophylaxis in determining outcome for 
patients with RHD. There are currently no studies that evaluated the role of SES and 
adherence to benzathine penicillin prophylaxis in patients with RHD using the health 
lifestyle theory. This study was aimed at determining the relationship between SES and 
clinical outcomes (heart failure and mortality) in patients with RHD and the role of 
adherence to BZP as a mediator between the relationship of SES and clinical outcomes 
(heart failure and mortality) in this population.  
In Chapter 1, I provided the background of what is known about rheumatic heart 
disease and its social determinants, the problem statement, the purpose of the study, the 
different research questions and hypotheses, the theoretical framework of the study, the 
nature of the study, the definitions, the assumptions, the scope and delimitations, the 
limitations, and the significance. 
In Chapter 2, I focus on discussion of literature in the area of socioeconomic 
status and RHD. I provided a discussion of RHD and RHD risk factors and then 
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subsequently provided a discussion of the theoretical framework, specifically studies that 
used the health lifestyle theory to examine the relationship between SES and RHD as 
well as the role of drug adherence on the relationship between SES and RHD. I then 
concluded with a discussion of the relationship of the study to previous research. 
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Chapter 2: Literature Review 
SES is  an important variable that predisposes to health disparities especially in 
people living with chronic diseases (Claussen, 2015; Sliwa, Acquah, Gersh, & Mocumbi, 
2016).  Furthermore, people with low income or from low SES families have been shown 
to be disproportionately burdened with higher morbidity and mortality from chronic 
disease especially cardiac diseases compared with those from more advantaged 
backgrounds (Hastert, Beresford, Sheppard, & White, 2015; Sommer et al., 2015; Wu, 
Woo, & Zhang, 2013). SES disparities may affect a person’s access to health care, their 
ability to pay for health services and possibly adherence to therapy all of which can have 
important impact on the outcome for such chronic diseases (Claussen, 2015; Stringhini et 
al., 2012, 2011). This study thus sought to assess the role of socioeconomic status on 
clinical outcomes for patients with RHD.  In addition, it examined how adherence to 
benzathine penicillin prophylaxis treatment regimen mediates the effect of 
socioeconomic status on clinical outcomes (heart failure and mortality) for these patients 
with RHD.  Exploring pathways between SES and clinical outcomes provides insight into 
the way in which health disparities might occur in persons with RHD (Claussen, 2015; 
De Dassel, Ralph, & Carapetis, 2015; Irlam, Mayosi, Engel, & Gaziano, 2013; Nulu, 
Bukhman, & Kwan, 2017; Stringhini et al., 2012, 2011). This may help inform decisions 
on developing framework for RHD control  as well as policies and interventions that can 
potentially eliminate these disparities and thence RHD (Irlam et al., 2013).  
This literature review addressed the predictive relationship between individual 
level SES and clinical outcomes in patients living with RHD. Major sections of the 
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chapter include the literature search strategy, conceptual framework, and review of key 
topics, including RHD epidemiology, pathogenesis, treatment patterns, prevention, SES, 
and adherence to benzathine penicillin prophylaxis. 
Literature Search Strategy 
A systematic literature search was conducted using African Journal online 
(AJOL), Cinahl, google scholar, Pubmed and Web of Science. In Pubmed, the following 
medical subject headings (MESH) and free text terms were used: Rheumatic heart 
disease” OR “Rheumatic valvular heart disease” OR “Rheumatic heart” OR “RHD” 
AND “clinical outcome” OR “heart failure” OR “admissions” AND “Benzathine 
adherence OR Compliance” OR “Secondary prophylaxis” OR “Penicillin adherence OR 
compliance” OR “BZP”. The same text word search was used in Google scholar, AJOL, 
CINAHL and Web of Science as in Pubmed. No search date limiter was used, however, 
studies in the last 5 years were preferred. In addition, studies had to be peer reviewed to 
be selected. Libraries were searched until March 2020. Studies were selected if they were 
written in English, included human subjects, defined benzathine prophylaxis and 
contained either rheumatic heart disease, or had clinical outcomes such as heart failure, 
mortality or death. Any study that failed to define benzathine prophylaxis adherence rates 
was excluded. A computerized bibliographical search was done that initially yielded 
1,342 articles but 46 publications were eventually selected for inclusion in this review 
because of their direct relevance to the study.  
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Theoretical Foundation 
The health lifestyle theory provided the foundation for this research work. The 
theory was formulated by Cockerham in 2005 and later expanded in 2013 (Cockerham, 
2005, 2013). Cockerham definesd health lifestyles as “collective patterns of health-
related behavior based on choices from options available to people according to their life 
chances” (Cockerham 2013). Cockerham’s health lifestyle theory was derived from 
Bourdieu’s seminal work on lifestyles (Cockerham 2005, 2013). Bourdieu postulated that 
lifestyle practices cluster in different strata of social space and that these different clusters 
correlated with the different social classes found in the society(Cockerham, 2005, 2013). 
According to Bourdieu, this class differences in lifestyles are hinged on the notion of 
“distance from necessity.” The distance from necessity is thought to produces 
dispositions to act (habitus), which generate practices (actions)(Bourdieu & de Saint 
Martin, 1976; Cockerham, 2005, 2013). When these dispositions are acted upon they 
result into the habitus that was the originator of the actions(Bourdieu & de Saint Martin, 
1976; Cockerham, 2005, 2013). The theory thus posited that the further a person is from 
the daily struggles for economic survival the more freedom and time such a person has to 
develop and refine personal tastes typical of the higher social classes (“taste of 
freedom”)(Bourdieu & de Saint Martin, 1976; Cockerham, 2005, 2013)i. In the same 
vein, the closer a person is to the daily struggles for survival (lower social classes) the 
less freedom and time such a person has to refine personal taste and thus adopt tastes 
consistent with a life of daily economic struggle in which acquiring items of necessity is 
critical (“taste of necessity”)(Bourdieu & de Saint Martin, 1976). Thus in this ensuing 
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power struggle, the freedom from the daily necessities of life becomes the major 
influence on decisions or actions taken by individuals(Bourdieu & de Saint Martin, 
1976). Therefore, the distance from economic necessity leads to a class-based, 
systematically unequal distribution of the instruments for appropriation of goods and thus 
generates other such class-based inequalities(Bourdieu & de Saint Martin, 1976). In his 
contribution to Bourdieu’s lifestyle theory, Cockerham  expanded the meaning of 
“lifestyle” to involve practices for maintaining health and preventing disease and not just 
consumption practices(Bourdieu & de Saint Martin, 1976; Cockerham, 2005, 2013). In 
his theoretical model, he conceptualized health lifestyles as consisting of a series of 
personal routines that converged into an aggregate form representative of specific groups 
and classes rather than a disjointed or uncoordinated behavior of disconnected individuals 
(Cockerham 2005, p. 56). In other words, as is the case with general lifestyle practices 
and tastes, health behaviors are correlated with socially determined structural variables 
that exist outside of the individual, such as class circumstances, age, gender, 
race/ethnicity, collectivities (religion, ideology), and living conditions(Bourdieu & de 
Saint Martin, 1976; Cockerham, 2005, 2013). Of all these structural variables the class 
circumstances, (socioeconomic class and the social and physical environments are the 
main determinant that configures health behavior(Bourdieu & de Saint Martin, 1976; 
Cockerham, 2005, 2013).  
Previously, researchers have explored the role of SES as an independent variable 
of interest in clinical outcomes for chronic diseases(Cockerham, 2014; Cockerham, 
Hamby, & Oates, 2017). Recently, country level SES was a subject of study by Zuhlke 
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and colleagues in their study of clinical outcomes for 3343 patients with RHD in 14 
African countries, Yemen and India as an independent variable of interest in defining 
clinical outcomes for persons with RHD (Zühlke et al., 2015). While country level SES 
may be a marker of societal affluence, it is unlikely going to be a good surrogate for 
individual level SES in predicting disease outcome which by all ramifications affects the 
individual and is thus most likely be more predictive by individual level factors 
(Claussen, 2015; Cockerham et al., 2017;  Zühlke et al., 2015). 
Health lifestyle theory is chosen for this study because of its applicability to 
chronic diseases such as RHD (Claussen, 2015; Cockerham, 2014; Zühlke et al., 2015). 
The health lifestyle theory postulates that the available life chances (structure) either act 
to constrained or expand the possible choices or decisions (agency) a person makes 
concerning their health (Cockerham, 2013). According to the health lifestyle theory, 
people’s health lifestyle is shaped by the structural influences to which they are exposed 
thereby limiting their choices to what is socially acceptable according to their 
socioeconomic class (Cockerham, 2013). RHD is a chronic disease that begins in 
childhood and if not appropriately treated continues into adult life (Cockerham, 2013; 
Mayosi, 2014; Nulu et al., 2017; Shah et al., 2013).  Low SES has several implications 
for the patient with RHD as it impacts not just the development of the disease but also the 
access to the necessary measures or treatment for the disease ( Liu, Lu, Sun, Zheng, & 
Zhang, 2015a; Mayosi et al., 2014; Watson, Jallow, Le Doare, Pushparajah, & Anderson, 
2015; L. Zühlke et al., 2015). In addition, RHD treatment relies on the patient’s 
adherence to treatment regime for congestive cardiac failure as well as the 4 weekly 
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benzathine penicillin injections for the prevention of ARF recurrence and thus the 
progression of the RHD to severe disease and eventually death ( Liu et al., 2015a; Mayosi 
et al., 2014; Watson et al., 2015; L. Zühlke et al., 2015). Thus, clinical outcomes for 
patients with RHD will largely depend on class circumstances and the patient’s ability to 
take action or decision about treatment regimens such as benzathine penicillin 
prophylaxis variables to which the health lifestyle theory provides an appropriate 
framework for asking research questions and predictive claims regarding SES and 
adherence (Cockerham et al., 2017).  
Adherence as a Health Behavior 
Chronic diseases have become important cause of morbidity globally due to the 
epidemiologic transition from infectious to non-infectious causes of disease(Harris, 2013; 
Hruby & Hu, 2015). Since chronic diseases are not easily cured by medical treatment, 
health lifestyle practices are becoming more important variables in determining clinical 
outcomes for patients with chronic diseases(Benjamin et al., 2018; Ettehad et al., 2016; 
Lyons, Lewis, Mayrsohn, & Rowland, 2014). As a result, patients with chronic diseases 
have to make efforts daily working towards slowing down the disease process in order to 
prevent premature death further underscoring the importance of life choices and by 
extension health lifestyle in predicting clinical outcomes for patients with chronic 
diseases(Benjamin et al., 2018; Ettehad et al., 2016; Lyons et al., 2014). This is seen in 
the case of RHD patients whose treatment regime affects all aspects of their daily life( 
Liu, Lu, Sun, Zheng, & Zhang, 2015b; Okello, Kakande, et al., 2017a). Applying 
Cockerham’s health lifestyle theory to RHD care, I argue that adherence to treatment in 
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RHD is a health lifestyle practice adopted to minimize illness and maximize health as is 
seen in other lifestyles practice like tobacco use, exercise, diet and utilization of 
preventive health services such as immunization. 
Conceptual Framework 
The conceptual framework for this study was derived from the health lifestyle 
theory which proposes that class circumstances (structure) play an important role both for 
adherence (agency) and for clinical outcomes in persons with RHD (Cockerham, 2005, 
2013; Cockerham et al., 2017; Goyal & Vijayvergiya, 2016; Mayosi, 2014). There have 
been studies that established a correlation between SES and many chronic diseases such 
as asthma, diabetes and coronary heart disease (Cockerham et al., 2017; Eisner et al., 
2011; Goyal & Vijayvergiya, 2016; Mayosi, 2014; Nandi, Glymour, & Subramanian, 
2014; Pudrovska & Anikputa, 2014; Sommer et al., 2015; Wu et al., 2013). Although 
recent studies have shown the important role of SES on the etiology and epidemiology of  
RHD, not much has been done to evaluate the correlation of SES and clinical outcomes 
for patients with RHD (De Dassel et al., 2015; Goyal & Vijayvergiya, 2016; Kumar & 
Tandon, 2013; Mayosi et al., 2014; Stewart, Carrington, & Sliwa, 2016; L. Zühlke et al., 
2015; L. J. Zühlke & Karthikeyan, 2013). Similarly, little is known about the mediating 
role of BZP adherence in the possible correlation between SES and clinical outcomes in 
patients with RHD (Goyal & Vijayvergiya, 2016; Kevat, Reeves, Ruben, & Gunnarsson, 
2017; Mayosi, 2014; Musoke et al., 2013; Okello et al., 2012; Okello, Longenecker, 
Beaton, Kamya, & Lwabi, 2017; Kevat, Reeves, Ruben, & Gunnarsson, 2017; L. Zühlke 
et al., 2015). In the light of this evidence and applying the framework of the health 
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lifestyle theory, I argued that adherence to treatment contributes to the correlation 
between SES and RHD clinical outcomes.  
Rheumatic Heart Disease 
Rheumatic heart disease, the chronic sequel of rheumatic fever is a disease 
associated with social disadvantage and poverty (Cannon, Roberts, Milne, & Carapetis, 
2017; Marijon, Mirabel, Celermajer, & Jouven, 2012; Nulu et al., 2017; Terreri & Len, 
2016; L. J. Zühlke et al., 2017). It has persisted in the developing countries because of the 
persistence of the social factors such as disorganized health system, poor housing, 
overcrowding and widespread poverty the predisposing factors to the acquisition, 
sustenance and persistence of the disease (Carapetis, Steer, Mulholland, & Weber, 2005; 
Stewart et al., 2016; Wilson, 2010). It is a disease that results from poorly treated or 
untreated group A beta hemolytic streptococcal pharyngitis especially in children 
between the ages of 5 and 15 years of age (Carapetis et al., 2005; Karthikeyan & 
Guilherme, 2018; Stewart et al., 2016; Wilson, 2010). Chronic RHD is associated with 
huge financial burden on the families of affected children (Marijon et al., 2012; Zühlke & 
Steer 2013; Zühlke et al., 2014). It renders a large proportion of children physically and 
educationally handicapped and therefore deprive the country of potential skilled 
workforce (Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Stewart et al., 2016; 
Wilson, 2010). In addition, it put a strain on the already lean health budget of these poor 
countries thereby further worsening already existing poor health indices in the population 
(Marijon et al., 2012; Zühlke & Steer 2013; Zühlke et al., 2014). 
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Epidemiology of Rheumatic Heart Disease 
Rheumatic heart disease (RHD) is currently the most common acquired heart 
disease in children and young adults living in the developing world especially those 
living in sub Saharan Africa (Watkins et al., 2017).  It used to be an important acquired 
heart disease in the United States and United Kingdom in the early twentieth century but 
with improvements in socioeconomic and living conditions, RHD completely 
disappeared except for occasional flares among immigrant populations (Kočevar et al., 
2017). Current estimates suggest that about 33 million people are living with RHD 
globally with a further estimated 280,000 new cases detected and a resultant 237,500 
estimated deaths globally in 2016. About 70- 80% of these deaths are said to occur in 
sub-Saharan Africa where poverty, malnutrition, poor hygiene and sanitation, 
overcrowding and poor access to health all act together to sustain the burden of the 
disease as well as the deaths occurring from the complications of the disease (Marijon et 
al., 2012; Zühlke  & Steer 2013; Zühlke et al., 2014). The persistence of these poverty 
defining problems in sub Saharan Africa is what is currently responsible for the 
persistence of RHD (Marijon et al., 2012; Zühlke & Steer 2013; Zühlke et al., 2014). 
Aetiopathogenesis of RHD 
RHD is a result of untreated or poorly treated group A beta hemolytic 
streptococcal pharyngitis that culminates into acute rheumatic fever (ARF) which if left 
untreated or become recurrent will eventually scar the endocardial lining of the heart and 
thus by extension the valves and their apparatus (Carapetis et al., 2005; Karthikeyan & 
Guilherme, 2018; Stewart et al., 2016; Wilson, 2010). This long term complication of 
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ARF is what is referred to as RHD (Carapetis et al., 2005; Karthikeyan & Guilherme, 
2018; Stewart et al., 2016; Wilson, 2010). Commonly, the initial streptococcal 
pharyngitis and its ensuing sequel of ARF occur in childhood especially in those children 
between 5 to 15 years.(Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Stewart et 
al., 2016; Wilson, 2010) However, the majority of those who present with RHD 
especially its severe form present in later childhood, adolescence and early adulthood 
(Watkins et al., 2017).  
RHD usually follows single or repeated episodes of ARF; an abnormal host 
attempt at eradicating the causative agent group A beta hemolytic streptococcal 
(GABHS) which cause pharyngitis (inflammation of the throat) (Karthikeyan & 
Guilherme, 2018; Stewart et al., 2016). ARF occurs because of the similarity between 
some parts of the GABHS bacterial cell wall and some parts of the host cardiac, brain, 
skin and synovial tissues (Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; 
Stewart et al., 2016; Wilson, 2010). This abnormal host immune response is seen in only 
about 0.3-3% of people who had the GABHS pharyngitis (Karthikeyan & Guilherme, 
2018; Mayosi, 2014; Stewart et al., 2016). Repeated GABHS infection is thought to be 
the initiating immunologic priming that predisposes to the development of ARF, the 
precursor of RHD (Karthikeyan & Guilherme, 2018; Mayosi, 2014; Stewart et al., 2016). 
This immunologic priming is also thought to be the main determinant of the age of onset 
of ARF and thus RHD which commonly peaks at between 5 to 15 years (Karthikeyan & 
Guilherme, 2018; Mayosi, 2014; Stewart et al., 2016).  
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Predisposing Factors to RHD 
RHD is a disease of poverty and social disadvantage hence its high burden in poor 
countries especially those in Africa, India and south East Asia (Animasahun, Deborah, 
Wobo, Itiola, & Oluwabukola, 2018; Watkins et al., 2017; L. J. Zühlke & Steer, 2013). 
The factors that predisposed to and sustained it in these regions are deeply rooted in 
poverty and social disadvantage (Animasahun et al., 2018; Watkins et al., 2017; L. J. 
Zühlke & Steer, 2013). However, RHD can also be seen in rich countries such as 
Australia where it is endemic among the indigenous or aboriginal populations as well as 
the immigrant populations where social disadvantage is common (Animasahun et al., 
2018; Watkins et al., 2017; Zühlke & Steer, 2013). Malnutrition, overcrowding, poor 
sanitation and hygiene and poor access to healthcare are all factors derived from poverty 
that predisposed to and sustain the burden of ARF/RHD.  Poverty is the single most 
important risk factor associated with RHD (Kumar & Tandon, 2013; Marijon et al., 2012; 
Watkins et al., 2017). Poverty breeds the social and environmental milieu that 
predisposes, cause and sustained the scourge of RHD (Kumar & Tandon, 2013; Marijon 
et al., 2012; Watkins et al., 2017). Conditions which promote high GABHS exposure are 
usually set in socioeconomic deprivation (Terreri & Len, 2016; Zühlke et al., 2017). 
Environmental factors. Overcrowding and poor sanitation are currently the most 
significant determinant of the development of RHD (Okello et a., 2013;Terreri & Len, 
2016;  Zühlke et al., 2017). In a case control study involving 486 participants (243 cases 
and 243 controls) in Uganda, Okello et al. (2013) reported an increased odd of having 
RHD with increasing household overcrowding (OR-1.35; 95% CI= 1.1-1.56) (Okello et 
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al., 2013). Jaine et al.,(2011) in an ecological study undertaken in New Zealand, showed 
a significantly increased rate ratio of ARF cases associated with crowding quintile, 
according to population-level data (Jaine, Baker & Venugopal  2011). Jaine et al. 
reported rheumatic fever rate of 9.6 per 100,000 seen in the most crowded quintile was 4 
times higher than the rate seen in the second most crowded quintile and 23 times more 
than that of the quintile with the least household crowding compared to the quintile with 
the least household crowding (Jaine et al., 2011). This effect remained even after 
adjusting for age, ethnicity, household income, and the density of children in the 
neighborhood suggesting. that household crowding is an independent factor associated 
with rheumatic fever (Jaine et ali., 2011). This effect remained even after adjusting for 
age, ethnicity, household income, and the density of children in the neighborhood 
suggesting. that household crowding is an independent factor associated with rheumatic 
fever (Jaine et al., 2011). 
 The association between overcrowding, GABHS infection, ARF and RHD has 
been the subject of research over the past 50 decades(Karthikeyan & Guilherme, 2018; 
Terreri & Len, 2016; Zühlke et al., 2017). Coffey, Ralph and Krause (2018) in a recent 
systematic review of the social determinants of GABHS pharyngitis, ARF and RHD 
examined 50 studies that reported on the association between household crowding and 
the risk of developing ARF/RHD.  A positive association between crowding and the risk 
of developing ARF was found in 9 of 16 (56.3%) studies reviewed and RHD in 9 of 15 
studies (60.0%).  Coffey reported that only 14 of the 50 studies reviewed showed 
consistent associations across all measures on the association between household 
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crowding and the risk of developing ARF/RHD (Coffey, Ralph & Krause 2018). While 
the quality of the studies may not be optimal, the evidence demonstrated in these 
researches supports an association between crowding and ARF risk(Coffey, Ralph & 
Krause 2018; Carapetis et al., 2005; Karthikeyan & Guilherme, 2018; Meira, Goulart, 
Colosimo, & Mota, 2005; Terreri & Len, 2016; Zühlke et al., 2017). Overcrowding the 
single most consistent factor in RHD epidemiology favors the spread of the GABHS 
between individuals especially in the face of poor ventilation which further reinforce the 
acquisition and spread of the organism(Islam & Majumder, 2016; Stewart et al., 2016; 
Zühlke & Steer, 2013). This pattern is frequent seen among the urban poor where rapid 
urbanization combine with poor housing to cause overcrowding and poor ventilation 
thereby predisposing to ARF and thereafter its chronic sequel, RHD (Islam & Majumder, 
2016; Stewart et al., 2016; Zühlke & Steer, 2013). The central role of overcrowding in 
the aetiopathogenesis of RHD has also been demonstrated in contemporary studies 
carried out in Australia and the developing world along with other societal markers of 
poverty such as poor access to health care, low maternal literacy levels, unhygienic 
environments and malnutrition (Islam & Majumder, 2016; Stewart et al., 2016; Watkins 
et al., 2017; Zühlke & Steer, 2013). Poor people will most likely live in poorly ventilated 
household with its attendant overcrowding and unhygienic surroundings breeding the 
organisms that are the harbinger of streptococcal pharyngitis the precursor of ARF the 
sequel of RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; 
Zühlke & Steer, 2013). 
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Malnutrition. Malnutrition is another poverty-related factor is an important 
predisposing factor to ARF and also RHD that is associated with weakened or poor 
immunity and thus an inability to naturally fight infectious diseases including GABHS 
(Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke & Steer, 
2013). Potentially, childhood malnutrition has a link with increased susceptibility to 
ARF/RHD probably due to the fact that malnutrition can increase susceptibility to 
developing aggressive autoimmune responses to GABHS infection (Islam & Majumder, 
2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke & Steer, 2013). However, since 
poor nutrition, household overcrowding and poor access to healthcare are associated with 
poverty, it is possible that malnutrition may just be a surrogate for poverty as a cause of 
ARF/RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke 
& Steer, 2013). Currently, there is no clear evidence linking malnutrition to GABHS 
and/or ARF/RHD apart from its association with poverty (Zuhlke & Steer 2013). 
Poor access to healthcare driven by poverty is another important predisposing factor to 
ARF and RHD (Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; 
Zühlke & Steer, 2013). An earlier study carried out by Gordis comparing outcome of care 
for black children aged 5 to 14 years with RHD in Baltimore enrolled in a comprehensive 
care program compared with similar aged matches group of RHD patient not enrolled in 
the same care program reported a 60% drop in incidence of ARF in those enrolled in the 
comprehensive care program (Gordis 1973). More recently, similar care programs 
instituted in Cuba focusing on health literacy and health promotion towards attitudinal 
change as well as improved access to BZP prophylaxis was shown to reduce the rates of 
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ARF by more than 50% in the general population (Gordis 1973; Nordet et al., 2008). 
While it is difficult to identify studies that directly assessed the impact of access to care 
on the risk of ARF.RHD, these comprehensive care programs serve to demonstrate the 
important role of access to care on the risk and burden of ARF/RHD in vulnerable 
populations (Gordis 1973; Nordet et al., 2008).  Poverty creates the structural factors that 
makes many in developing countries to seek alternative care rather than present to 
hospitals(Islam & Majumder, 2016; Stewart et al., 2016; Watkins et al., 2017; Zühlke & 
Steer, 2013). This thus means that GABHS, a potentially treatable and curable infection 
may be missed, poorly treated or not treated at all further predisposing the child or young 
adult to the risk of ARF and thus RHD(Islam & Majumder, 2016; Stewart et al., 2016; 
Watkins et al., 2017; Zühlke & Steer, 2013). Where this ARF becomes recurrent, further 
damage is incurred on the heart with worsening of outcomes leading to frequent or 
chronic heart failure potentially culminating in death(Cannon et al., 2017; Kumar & 
Tandon, 2013; Mayosi et al., 2014; Shah et al., 2013; Zühlke et al., 2015).  
Treatment Patterns for Rheumatic Heart Disease 
Rheumatic heart disease being a chronic heart condition comes with a lot of 
challenges for patients when we consider treatment options(Cannon et al., 2017; Nulu et 
al., 2017; Zühlke et al., 2015). Access to appropriate intervention in an environment with 
poorly developed health care infrastructure where RHD is endemic is crucial and may be 
the missing link in appropriate and correct management of the disease in these patients 
with established heart valve disease (Shah et al., 2013). For example, the REMEDY 
study which evaluated 3343 RHD patients across 14 countries in Africa, India and 
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Yemen showed that more than 50% of patients who are eligible for BZP secondary 
prophylaxis, an effective tool for preventing worsening and recurrent ARF/RHD were not 
receiving the therapy (Zuhlke et al., 2015). It is thus important that improved access to, 
and affordability of, essential medicines such as benzathine penicillin, heart failure drugs, 
and anticoagulants to prevent thromboembolic events be the main focus of policy makers 
and clinicians alike (Regmi & Wyber, 2013; Shah et al., 2013; L. Zühlke et al., 2015).  
Rheumatic heart disease being a valvular heart disease is associated with 
mechanical disturbances of cardiac valve function especially the mitral valve which 
commonly presents with mitral incompetence leading to regurgitation and back flow of 
blood thus predisposing to frequent heart failure in those affected (Carapetis, Brown, 
Maguire, & Walsh, 2012; Regmi & Wyber, 2013; Boglarka Remenyi, Elguindy, Smith, 
Yacoub, & Holmes, 2016; Shah et al., 2013; Smith, Zurynski, Lester-Smith, Elliott, & 
Carapetis, 2012; Zühlke et al., 2015). Heart failure is the most frequent complication seen 
in about 30 percent of new patients seen with RHD (Carapetis et al., 2012; M. Liu et al., 
2015b; Mehta et al., 2016; Regmi & Wyber, 2013; Boglarka Remenyi et al., 2016; Shah 
et al., 2013; Smith et al., 2012; L. Zühlke et al., 2015). In addition, it is the most frequent 
cause of death in those affected with RHD with about 17% dying within 2 years of 
enrolment in a follow up care program especially when the disease occurs early in 
childhood (Carapetis et al., 2012; Smith et al., 2012; Zuhlke et al., 2015). Heart failure 
management with diuretics is the main stay of treatment for most patients with 
symptomatic RHD especially those with chronic heart failure  (Carapetis et al., 2012; 
Smith et al., 2012). The availability of potent diuretics especially the loop diuretics has 
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helped to improve the control of heart failure in these patients with RHD thus reducing 
the rate of death associated with heart failure in these patients (Nieuwlaat et al., 2014; 
Nulu et al., 2017; Shah et al., 2013). 
Prevention Strategy for Rheumatic Heart Disease 
Rheumatic heart disease is wholly preventable using simple, basic, cost effective 
public health measures such as improvement in living conditions and nutrition 
rehabilitation (Irlam et al., 2013; Gordis 1973;Nieuwlaat et al., 2014; Nulu et al., 2017; 
Regmi & Wyber, 2013; Remenyi, Carapetis, Wyber, Taubert, & Mayosi, 2013; Shah et 
al., 2013). Evidence from the United States suggest that improvements in living 
conditions, sanitation and poverty reduction was responsible for the greater than 70% 
drop in cases of ARF/RHD seen in the 20th century (Irlam et al., 2013; Gordis 
1973;Nieuwlaat et al., 2014; Nulu et al., 2017; Regmi & Wyber, 2013; Remenyi et al., 
2013).Its persistence in the developing countries especially Sub Saharan Africa 
exemplifies the failure of coordinated efforts of public health practitioners, policy makers 
and implementers (Gordis 1973; Nulu et al., 2017; Remenyi et al., 2013). Such 
prevention efforts must be targeted at the social determinants of the disease as well as the 
improvement of access to care for streptococcal pharyngitis as well as those who develop 
the disease (Irlam et al., 2013; Nordet et al., 2008;  Remenyi et al., 2013; Zühlke & 
Karthikeyan, 2013). These measures are needed in order for meaningful progress to be 
made at the control and prevention of the disease (Remenyi et al., 2013). Such prevention 
and control measures for RHD must be targeted at the reduction of household crowding, 
timely diagnosis and appropriate antibiotics for bacterial pharyngitis and – in people who 
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develop rheumatic fever – antibiotic prophylaxis over several years to prevent disease 
progression (Irlam et al., 2013;  Irlam, Mayosi, Engel, & Gaziano, 2013; Remenyi et al., 
2013).  
Role of School based Echocardiography screening in the Prevention of RHD 
Community based echocardiographic screening especially in school children who 
happen to bear the brunt of the disease is said to increase the detection rates for RHD by 
about 10-15 times when compared with cardiac auscultation and  thus proved to be an 
important tool for the detection of asymptomatic RHD (Beaton et al., 2012; Irlam et al., 
2013;  Irlam et al., 2013; Remenyi et al., 2013; Rothenbühler et al., 2014; Shah et al., 
2013). Early detection of RHD especially in those who are yet to show signs of the 
disease opens the way for early initiation of BZP prophylaxis for the prevention of 
GABHS episodes and as such recurrence of ARF (Beaton et al., 2012; Irlam et al., 2013;  
Irlam et al., 2013; Remenyi et al., 2013; Rothenbühler et al., 2014; Shah et al., 2013). 
Echocardiographic screening for RHD in school children has been demonstrated to 
increase the uptake of BZP prophylaxis by about 40% and thus helped reduce the onset of 
severe disease and other complications associated with  RHD (Cannon et al., 2017; 
Mason, Retzer, Hill, Lincoln, & Centers for Disease Control and Prevention (CDC), 
2015; Rothenbühler et al., 2014). In Fiji, Engelman reported that overall admission rates 
in clinically diagnosed RHD in symptomatic children is 4 times higher compared with 
that of echocardiography-based screening detected asymptomatic children. (RR 4.3, 95% 
CI 2.8–6.8) (Engelman et al., 2017). In addition, RHD-related admissions bed days were 
higher in the clinically diagnosed group compared with the echocardiography-based 
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screening-detected group (IRR 6.6, 95% CI 5.6–7.8) (Engelman et al., 2017). 
Echocardiography based school screening is thus significantly associated with reduced  
morbidity and mortality(Engelman et al., 2017).  A similar effort in Australia has 
demonstrated the same results for aboriginal children who bear the brunt of the disease in 
Australia (Carapetis et al., 2012; Parks, Smeesters, & Steer, 2012; Steer & Carapetis, 
2009). The advent of echocardiography has thus helped in no small measure towards not 
just making an early diagnosis but also in the prevention and control of RHD globally 
(Carapetis et al., 2012; Marijon, Celermajer, & Jouven, 2017; Parks et al., 2012; 
Rothenbühler et al., 2014; Steer & Carapetis, 2009).  
Penicillin Secondary Prophylaxis 
In a classic study suing a cohort design, Stollerman, Russoff and Hirschfeld 
(1955) showed that secondary prophylaxis using 4 weekly 1.2 mega units intramuscular 
BZP was successful in preventing ARF recurrence in patients followed up for 20 months 
(Stollerman, Russoff & Hirschfeld 1955). In their report, none of the patients on BZP 
developed ARF compared with their counterparts on oral penicillin or sulfadiazine 
(Stollerman et al., 1955). Adequate Penicillin prophylaxis described as at least 80% of the 
prescribed annual dose improved outcomes and reduces the risk of death especially where 
access to healthcare is limited (Nordet et al., 2008; Nulu et al., 2017). Recently, de Dassel 
et al., in a review of register data of Australian patients with RHD reported a 4-fold 
increase in the odds of having ARF in patients who had suboptimal (<80% of annual 
doses) adherence to BZP (de Dassel et al., 2018). Intramuscular benzathine penicillin 
(BZP) injections serve as the main prophylaxis and a key component of RHD control 
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programs (Irlam et al., 2013; Manji et al., 2013; Regmi & Wyber, 2013; Remenyi et al., 
2013; Smith et al., 2012; Watson et al., 2015;  Zühlke et al., 2017). This approach is 
aimed at preventing group A beta-hemolytic streptococci (GABHS) streptococcal 
infections the harbinger of ARF  and by extension subsequent recurrent episodes of ARF 
the precursor of RHD ( Irlam et al., 2013; Nulu et al., 2017). Current recommendations 
by the World Health Organization (WHO) stipulates a 3-4 weekly BZP injection for a 
duration dependent on factors including age, time since the last episode of ARF, risk of 
streptococcal infections in the area and presence of RHD (Rémond, Coyle, Mills, & 
Maguire, 2016a). Based on the WHO guidelines, secondary prophylaxis is advised for at 
least 5 years after the last episode of ARF or until the age of 18 years (whichever is 
longer) and for a greater length of time for persons who had cardiac involvement at the 
initial episode of ARF or in those with established RHD (Remenyi et al., 2013; Rémond 
et al., 2016a). 
For a successful RHD prevention, a well-coordinated BZP prophylaxis hinged on 
good drug supply chain and easily accessible centers for BZP injection is key (Nieuwlaat 
et al., 2014; Watson et al., 2015; Zühlke & Karthikeyan, 2013). In the more than 50 years 
of using penicillin in the treatment of GABHS pharyngitis associated with ARF/RHD, 
antibiotic resistance has not been reported against penicillin G and its generics (Kumar & 
Tandon, 2013; Liu et al., 2015a). This has made penicillin G an excellent and yet useful 
tool for the much needed RHD control program globally (Kumar & Tandon, 2013; Liu et 
al., 2015a). While concerns about penicillin allergy and the pains of intramuscular 
injections have been the main hindrances to the widespread uptake of BZP prophylaxis in 
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RHD endemic areas, current evidence suggest a low or near absent presence of serious 
anaphylactic reactions to penicillin (Kumar & Tandon, 2013; Liu et al., 2015a). 
Clinical Outcomes in RHD 
RHD a disease of children and young adults is associated with many 
complications(Kumar & Tandon, 2013; Liu et al., 2015a; Stewart et al., 2016; Watkins et 
al., 2017). Patients with RHD are at an increased risk for congestive heart failure, 
arrhythmias, stroke and infective endocarditis( Liu et al., 2015a; Zühlke et al., 2015). The 
REMEDY study, a 2 year prospective study which contains the largest contemporary data 
on the outcomes of clinically diagnosed RHD from multiple centers across 12 different 
African countries, Yemen and India reported congestive cardiac failure in 20% of the 
patients seen at baseline (Zühlke et al., 2015). In addition, a high mortality rate was noted 
especially in those who had severe disease, heart failure or were older than 20 years at the 
time of being recruited into the study (Zühlke et al., 2015). A similar study conducted in 
Fiji though using a younger cohort of patients reported similar outcomes to that seen in 
the REMEDY study though with a higher mortality rate (Engelman et al., 2017). Severe 
disease and a frequent occurrence of heart failure are key predictors of death for patients 
with RHD as seen in both the REMEDY and the Fiji study (Engelman et al., 2017; 
Zühlke et al., 2015). 
 Disease severity at diagnosis has been consistently shown to be a major predictor 
of clinical outcome for patients with RHD ( Liu et al., 2010; Nulu et al., 2017; Okello, 
Kakande, et al., 2017a; Zühlke et al., 2015). In Australia, Cannon et al., using RHD 
register information on 591 Indigenous residents diagnosed with RHD in the Northern 
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Territory between the ages of 5 and 24 years over a 14 year period observed that 30% of 
the patients had severe disease at baseline (Cannon et al., 2017). For these patients with 
severe disease, Cannon et al., reported a 5 year mortality rate of 10% compared no deaths 
in those who presented with mild RHD at diagnosis (Cannon et al., 2017).  Despite this 
favorable mortality rate, 11.4% of those who presented with mild RHD still progressed to 
severe RHD within a 10 year period with half of them requiring valvular surgery(Cannon 
et al., 2017). 
Even though there is no conclusive evidence for a gender predilection in the 
etiology of RHD, women and girls have been shown to be disproportionately affected 
with RHD(Watkins et al., 2017; Zühlke et al., 2015). Women living with RHD and who 
get pregnant are also prone to pregnancy related complications such as heart failure, 
premature delivery, fetal death and even maternal death(Watkins et al., 2017; Zühlke et 
al., 2015). However, gender on its own has not being shown to be an independent 
predictor of death or progression of disease in patients with RHD (Liu et al., 2010).  
Socioeconomic Status and Clinical Outcomes in RHD 
Clinical outcomes for chronic diseases have been shown to be worst as one goes 
down the socioeconomic quintiles(Cannon et al., 2017; Centers for Disease Control and 
Prevention, 2018; Zühlke et al., 2015). Chronic diseases such as cystic fibrosis  have been 
demonstrated to be associated with worst outcomes especially death in patients who are 
poor and uneducated (Oates et al.,  2016).  The socioeconomic gradient in clinical 
outcomes for heart related disorders such as myocardial infarction was shown to be 
associated with the increased in the modifiable risk factors for cardiovascular disease 
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such as hypertension, dyslipidemia and tobacco smoking and not so much because of the 
low socioeconomic status of the patients (Choudhry et al., 2014). This however has not 
been conclusively demonstrated in RHD. While the REMEDY study showed a higher 
mortality rate as well as incident heart failure rates in patients from low income and low 
middle income countries, causality cannot be established because of the ecological theory 
fallacy (Zühlke et al., 2015).  
Socioeconomic Status and Benzathine Penicillin Adherence in RHD 
A relationship between socioeconomic status and adherence in RHD has not been 
conclusively determined (Goyal & Vijayvergiya, 2016; Watson et al., 2015; Zühlke et al., 
2015).  A person’s SES is said to affect their ability to access and utilize health 
information and services (Cockerham et al., 2017; Eisner et al., 2011; Goyal & 
Vijayvergiya, 2016; Watson et al., 2015; Zühlke et al., 2015). Low health literacy as well 
as absence of any formal education has been shown to predispose to poor adherence to 
penicillin prophylaxis in patients with RHD living in low and lower middle income 
countries (Ralph. et al., 2016; Huck et al., 2015; Rémond et al., 2016). While no causal 
link has been established between RHD adherence rates and socioeconomic status of the 
individual patient, unemployment, a surrogate for SES was shown to be associated with 
poor adherence to BZP prophylaxis in Uganda (Longenecker et al., 2016).  In India, a 
cross sectional evaluation of 500 patients with RHD on BZP prophylaxis reported a high 
rate of poor adherence to BZP prophylaxis (Shah et al., 2013). Low SES, being 
uneducated and residing in a rural area was found to be significant determinants of poor 
access to BZP prophylaxis (Shah et al., 2013). In their prospective study of 449 Ugandan 
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patients with RHD, Okello et al. reported that poor adherence to BZP prophylaxis or 
suboptimal adherence to benzathine penicillin injections (BZP injections less than 80% of 
total annual injections) was associated with a high rate of incident heart failure and 
mortality (Okello, Kakande, et al., 2017a). Heart failure and also mortality was directly 
correlated with the rate of progression from mild to severe disease (Okello, Kakande, et 
al., 2017a). 
Adherence and Clinical Outcomes in RHD 
Adherence in RHD has been variously defined depending on the study design and 
end point( Islam & Majumder 2016; Kevat et al., 2017; Lam & Fresco, 2015). However, 
adherence defined on the basis of the proportion of BZP injections received as a fraction 
of expected total annual injections has recently been widely used in estimating adherence 
rates(Okello, Kakande, et al., 2017b). An adherence rate of at least 80% is currently the 
most widely accepted cut off point for optimal or adequate adherence rates for BZP 
prophylaxis in RHD(Okello, Kakande, et al., 2017b).  Longitudinal studies on adherence 
to BZP prophylaxis has been shown to be associated with an improved outcome for 
patients diagnosed with RHD especially those with mild disease(Mehta et al., 2016; 
Okello, Kakande, et al., 2017b). Adequate adherence successfully reduce the rate of ARF 
recurrences and hence the progression and severity of RHD in patients already living 
with RHD (Chamberlain-Salaun, Mills, Kevat, Rémond, & Maguire, 2016; Mehta et al., 
2016; Okello, Kakande, et al., 2017b; Rémond et al., 2016a).   
Adherence as the Mediating Pathway between SES and Clinical Outcomes in RHD 
There are currently no studies that evaluated the mediatory role of benzathine penicillin 
adherence on the relationship between SES and clinical outcomes in patients with RHD 
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(Huck et al., 2015; Kevat et al., 2017; Okello, Kakande, et al., 2017b; Ralph et al., 2016). 
However, the role of medication adherence linked with SES on health outcomes had been 
studied in other chronic disease conditions such as HIV, asthma, diabetes and 
hypertension(Burch et al., 2016;Huck et al., 2015; Nandi et al., 2014; Oates, Britton, 
Gamble, & Harris, 2015; Okello, Kakande, et al., 2017b; Ralph et al., 2016; Wayda et al., 
2018). In one such study, Burch et al., assessing the effect of socioeconomic status 
(financial hardship, non-employment, rented or unstable housing status, and non-
university education) on virologic outcomes in people receiving antiretroviral treatment 
(ART) for HIV in the UK, reported a strong association between lower socioeconomic 
status with ART non-adherence and virologic non-suppression on ART(financial 
hardship vs none 2·4, 95% CI 1·6–3·4; non-employment 2·0, 1·5–2·6; unstable 
housing vs homeowner 3·0, 1·9–4·6; non-university education 1·6, 1·2–2·2) (Burch et 
al., 2016).  When they adjusted for adherence to ART in their logistic model, there was a 
weakening in the association between SES and virologic outcomes further suggesting that 
the associations between low socioeconomic status and virologic non-suppression are 
probably mediated mainly through ART non-adherence (Burch et al., 2016).  
While ART drugs may differ significantly from BZP in being oral medications 
rather than intramuscular injection, the findings by Burch et al., still underscores a need 
for more research on adherence to BZP prophylaxis as a potential mediator of the 
relationship between SES and clinical outcomes in patients with RHD(Burch et al., 
2016). This is even made more plausible because of the dearth of information in the 
literature on adherence as a potential mechanism of socioeconomic disparities in clinical 
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outcomes for RHD patients (Goyal & Vijayvergiya, 2016; Oates et al., 2016). Most 
studies of adherence in RHD use cross-sectional research designs that limit conclusions 
regarding potential pathways of SES, medication adherence, and clinical 
outcomes(Chamberlain-Salaun et al., 2016; Ralph et al., 2016; Rémond et al., 2016a). 
Summary and Conclusions 
From this literature review, it can be seen that previous studies employed mainly 
observational research designs such as cross-sectional and cohort studies to investigate 
clinical outcomes in patients with RHD. In the same vein, this literature review also 
shows that previous research to assess the relationship between SES, adherence, and 
clinical outcomes in patients with RHD used both cross sectional and prospective cohort 
designs. Several measures of SES were used in the literature, including family income, 
geographic location of residence, and educational attainment. Measures of adherence to 
BZP prophylaxis in previous studies include patient self-report and medical provider 
assessments. Even though the BZP adherence rates seen in most of the studies reviewed 
was sub-optimal, in some countries where RHD is endemic (India, Cuba and New 
Zealand) the adherence rates were reported as good. However, there was varying 
adherence rates reported for individual patients (0-100% of prescribed injections) with 
some patients receiving inadequate BPG injections (adherence rates less than 80%) while 
others received appropriate prophylaxis (Adherence rates greater than 80%).   Due to the 
observational nature of most of the studies reviewed, it was difficult to conclusively link 
adherence to BPG with patient socioeconomic status.  
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There are critical gaps in assessing patient self care with respect to chronic 
disease management as seen from the literature reviewed. Socio-cultural factor was 
identified as a key variable in predicting treatment adherence and health outcomes in 
patients with chronic diseases.  
In Chapter 3, I provided a description of the research design and justification for 
the choice of the research design. In addition, I provided a description of the sample and 
details of the selection criteria of study participants, description of the REMEDY study as 
well as an overview of the variables in the study. The data collection process as well as 
analysis was also discussed. The chapter concluded with a discussion of the ethical 
considerations of this study. 
43 
 
Chapter 3: Research Method 
The aim of this study was to determine the relationship between SES and clinical 
outcomes (incident heart failure and mortality rates) in patients with RHD. It also sought 
to determine the role of adherence to BZP as a mediator between the relationship of SES 
and clinical outcomes (Incident heart failure and mortality) in patients with RHD. 
Research Design and Rationale 
This research implemented a retrospective cohort design by using deidentified 
secondary data from a previously collected data of RHD patients in Nigeria who 
participated in a multicenter, multi-country prospective registry of patients with RHD, 
called REMEDY to address the research questions.  The REMEDY study prospectively 
collected socio-demographic, clinical and echocardiographic data from 3343 
symptomatic RHD patients presenting to the outpatient clinic, inpatient care facilities and 
emergency room services of the 25 participating hospitals spread across 12 African 
countries, India and Yemen between January 2010 and 2014. The Nigerian registry 
contained 256 symptomatic RHD patients. Each patient was followed up over a 2-year 
period (Karthikeyan et al., 2012; Zuhlke et al., 2014).  Treatment adherence was 
evaluated at each visit and clinical outcomes were recorded if it occurred during the study 
follow-up period (Karthikeyan et al., 2012; Zuhlke et al., 2014). A cohort design was 
appropriate for this secondary data analysis because of the need to compare two groups of 
patients classified based on their SES (Gordis 2015). In addition, a cohort study design 
helped to show the temporal sequence between the exposure (SES) and the outcome 
(mortality, heart failure) since the subjects (RHD patients) are known to be free of the 
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outcome of interest at the time of recruitment into the REMEDY study when their 
exposure status was established (Gordis 2015). In a previous report of the clinical 
outcomes in RHD patients prospectively studied, Zuhlke et al., (2015) had reported a 
heart failure rate of about 7% and a mortality rate of 17% mostly in patients from low and 
low middle income countries thereby underscoring the need for this retrospective cohort 
study aimed at evaluating the relationship between individual level SES and clinical 
outcomes in patients with RHD. (Zuhlke et al., 2015). I hypothesized that SES may affect 
heart failure (HF) and mortality rates in patients with RHD. In addition, I also 
hypothesized that the relationship between SES and clinical outcomes in these patients 
will be influenced by their respective adherence to BZP prophylaxis (de Dassel et al., 
2018; Watkins et al., 2017). The availability of this secondary data already collected with 
information on BZP adherence, HF rates and mortality rates provide an important 
opportunity for testing these hypotheses (de Dassel et al., 2018; Gordis 2015). Secondly, 
exploring how adherence mediates the association between SES and clinical outcomes is 
needed to advance knowledge of mechanisms which may play a role in the SES-health 
gradient even though the strength of the association between drug adherence and SES in 
chronic diseases management is unclear (Choudhry  et al., 2014;Dhar  et al., 2017). RHD 
being a chronic disease will thus benefit from an understanding of this mechanism on the 
rates of adherence especially as it affects BZP adherence, an important but cost-effective 
useful tool for management. 
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Data Sources 
Data for this secondary data analysis was obtained from the Nigerian site of the 
global rheumatic heart disease registry (REMEDY) study. The REMEDY study enrolled 
256 symptomatic RHD patients into the Nigerian registry at the point of contact with the 
cardiologist in each participating hospital after obtaining written informed consent by a 
trained research nurse. Socio-demographic data such as age, sex, educational attainment, 
occupation, income and racial /ethnic affiliations were collected using a standardized 
questionnaire after obtaining informed written consent (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). Clinical parameters were collected by the research clinician either from the 
patient records or through oral interview as the case may be (Karthikeyan et al., 2012; 
Zuhlke et al., 2014). Patient demographic data, clinical findings, and details of 
electrocardiographic (ECG) and echocardiographic findings were recorded on structured 
case record forms (Karthikeyan et al., 2012; Zuhlke et al., 2014). Details of medications 
prescribed, with particular reference to penicillin prophylaxis, antithrombotic and 
antiplatelet drugs, and antiarrhythmic medications, at study entry, 1-year follow-up, and 
at the end of 2 years were also collected (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
Adherence to penicillin prophylaxis was assessed by obtaining injection records and/or 
direct questioning (Karthikeyan et al., 2012; Zuhlke et al., 2014). Adherence to penicillin 
prophylaxis was calculated based on percentage of prescriptions received over the 12 
months preceding enrolment or follow up visits as the case may be (Karthikeyan et al., 
2012; Zuhlke et al., 2014). Echocardiography data was obtained in the echo laboratory or 
if recently done, from the case records of the patient (Karthikeyan et al., 2012; Zuhlke et 
46 
 
al., 2014). For improved diagnostic accuracy, standard operating procedures adapted 
from the WHO guidelines for the diagnosis of RHD was used for uniformity in 
classifying the patient as having RHD or not (Karthikeyan et al., 2012; Zuhlke et al., 
2014). Both the color and spectral Doppler signals must be holodiastolic for aortic 
regurgitation or holosystolic for mitral regurgitation in order for a diagnosis of RHD to be 
entertained (Karthikeyan et al., 2012; Zuhlke et al., 2014). The Doppler signal must be of 
high velocity, either from a pulsed or continuous wave (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). These criteria can readily distinguish a small color jet of physiological 
regurgitation in a normal person from pathological regurgitation in patients with RHD 
(Karthikeyan et al., 2012; Zuhlke et al., 2014). Assessment of severity of valve lesions, 
left ventricular (LV) systolic dysfunction (i.e. left ventricular ejection fraction, LVEF, 
less than 54%  or  fractional shortening less than 28% in children and adults), and LV 
dilatation (i.e. LV end diastolic dimension greater than 50 mm in children and  55 mm in 
adults was done using the AHA guidelines). Patients in this study were identified through 
registry data for inclusion (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
Follow-up—All patients recruited were made to undergo 2 follow-up visits, one at 12 
months and one at 24 months (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
Echocardiogram was performed at both follow-up visits (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). In addition, assessment for outcomes (heart failure, ARF recurrence, death, 
use of secondary benzathine penicillin prophylaxis, oral anticoagulation and surgical 
intervention) was also done at each follow-up visit and at any other visits that the patient 
makes to the hospital as part of usual care (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
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Outcomes were based on standard definitions (Karthikeyan et al., 2012; Zuhlke et al., 
2014). All deaths were recorded in a case record form and the cause ascertained by 
review of the relevant source documents such as autopsy reports, physician records or in 
the case of death at home an interview of a close relative or care giver who witnessed the 
events preceding death by the managing physician (Karthikeyan et al., 2012; Zuhlke et 
al., 2014). Morbidity such as new congestive cardiac failure was ascertained by review of 
hospitalizations records of the patient as well as interview by the managing physician 
(Karthikeyan et al., 2012; Zuhlke et al., 2014). Any additional information needed was 
obtained by contacting one of the patient’s physicians or next of kin (Karthikeyan et al., 
2012; Zuhlke et al., 2014). For maintaining internal validity, an independent monitoring 
board was constituted who at random select a sample of 10% of the locally adjudicated 
events for audit in order to ascertain compliance with protocol and thus maintain 
consistency with the study definitions (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
The data on these patients was coded so that no information can be linked to specific 
individuals (Karthikeyan et al., 2012; Zuhlke et al., 2014). Patients were identified 
throughout the study duration by the study number allotted to them at the time of 
enrollment (Karthikeyan et al., 2012; Zuhlke et al., 2014). Confidentiality was maintained 
by restricting access to de-identifiers to only the site PIs and in some cases by study 
clinicians where there is need for medical intervention (Karthikeyan et al., 2012; Zuhlke 
et al., 2014).  The study data were archived by the principal investigator in the 
department of Medicine, University of Cape Town. To access the data for this study, a 
permission letter to access the data was submitted to the steering committee of the global 
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rheumatic heart disease registry through the principal investigator. The steering 
committee permitted my use of the data after reviewing my application and research 
proposal.  
Study Setting and Population 
This study utilized a retrospective cohort design on data collected in Nigeria from 
2010 to 2014 as part of the global rheumatic heart disease (REMEDY) study, a 
multicenter, multi-country prospective study that collected data from symptomatic RHD 
patients across 12 African countries, India and Yemen (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). The Nigerian site consisted of 5 participating centers spread across the north 
(Aminu Kano Teaching Hospital, Kano), central (Jos University teaching Hospital, Jos 
and University of Abuja Teaching Hospital, Gwagwalada) and southern parts of the 
country (University College Hospital, Ibadan and Federal Medical Center, Abeokuta). 
Symptomatic RHD patients were recruited from outpatient clinics, emergency rooms and 
inpatient care wards at baseline and subsequently followed up over two years at the 
participating sites (Karthikeyan et al., 2012; Zuhlke et al., 2014).  This study formed two 
cohorts based on the socioeconomic groupings as classified using Oyedeji socioeconomic 
classification system (Oyedeji 1985). The socioeconomic variables used were those 
variables collected on the patients at the time they were recruited into the REMEDY 
study (Zuhlke et al., 2014). One cohort (Cohort 1) contained patients with low SES while 
the second (Cohort 2) contained patients with middle to higher SES. SES classification 
was done based on the educational attainment and occupation of the patients themselves 
or their caregivers in case of children as proposed by Oyedeji (Oyedeji 1985).  
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The baseline characteristics included age at entry, sex, educational attainment for 
adults or parental educational attainment for children, weight, height, disease severity at 
enrolment, heart failure status, New York Heart Association (NYHA) class and 
benzathine penicillin prophylaxis status at enrolment.  The outcome for heart failure was 
identified based on the report of events such as hospitalization or treatment for heart 
failure as reported by the managing physician and documented in the case record form 
(CRF) (Karthikeyan et al., 2012; Zuhlke et al., 2014). The mortality was based on 
physician CRF report, autopsy report or family report as detailed in the study events 
forms (Karthikeyan et al., 2012; Zuhlke et al., 2014). The follow-up time for each patient 
was counted from day of entering the study to onset of the study outcome or end of the 
study (Karthikeyan et al., 2012; Zuhlke et al., 2014).   
Power Calculations 
Power analysis was conducted using G*Power (version 3.0.10) based on a 
Poisson regression model in order to determine the needed sample size (Cumming 2012; 
Kline 2013). In this calculation, using a significance level of 0.05, effect size of 0.3 
(Kline 2013), z statistics of 1.959964 and a power of 0.80, the total minimum study 
population needed to answer research question 1 is 130 (65 in each cohort). However, all 
patients contained within the Nigerian database of the REMEDY study were recruited 
into the study (Kline 2013). The calculation output is depicted in figure below.   
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Figure 1. Showing cases needed for research questions α is the rejection zone while β is 
the type 2 error rate.  
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Data Collection Procedure 
This study utilized the data collected from the REMEDY study (Karthikeyan et 
al., 2012; Zuhlke et al., 2014). The REMEDY study had collected clinical, socio-
demographic, and echocardiographic data from all the patients enrolled into the registry 
using an eleven-page questionnaire that is divided into sections for ease of administration 
at baseline, 12 months and 24 months (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
Each section began with standard operating procedures, codes and definition of variables 
to be collected in that section (Karthikeyan et al., 2012; Zuhlke et al., 2014). The first 
page contained questions on sociodemographic variables such as age, gender, education, 
ethnicity, income and occupation (Karthikeyan et al., 2012; Zuhlke et al., 2014). The next 
eight pages contain questions about the clinical history of the patient including 
echocardiography information as well as other investigations done (Karthikeyan et al., 
2012; Zuhlke et al., 2014). The last 2 pages contain drug history of the patient and 
information on number and adherence to BZP injection (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). A sample of the questionnaire is attached as Appendix A. Each patient was 
recruited at baseline by a research nurse after obtaining written informed consent 
(Appendix B). These patients were subsequently followed up annually for 2 years 
(Karthikeyan et al., 2012; Zuhlke et al., 2014). At each visit, the patients were assessed 
for the occurrence of adverse outcomes (such as death, congestive heart failure (CHF), 
stroke or transient ischemic attack (TIA), recurrence of acute rheumatic fever (ARF), and 
infective endocarditis (IE)), use of secondary antibiotic prophylaxis and oral 
anticoagulation medication, and need for valve intervention or surgery (Karthikeyan et 
52 
 
al., 2012; Zuhlke et al., 2014). The study had a standard protocol for the diagnosis of all 
outcomes including congestive cardiac failure and death (Karthikeyan et al., 2012; 
Zuhlke et al., 2014).  
Definition of Variables 
Independent Variable  
Socioeconomic status (SES). In epidemiological research, various indicators of 
SES have been used. Depending on the context, the population studied and the outcome 
measured, any of income, wealth, education and occupation may be used in isolation or 
in any combination in assessing SES (Oakes & Rossi, 2003).  Socioeconomic status 
(SES), a fundamental construct in the social and health sciences, is a measure of access to 
resources, such as financial resources and material goods, power, social networks, health 
care, and educational opportunities (Oakes & Rossi, 2003). SES indicates one’s position 
in the social hierarchy, and often determines one’s life chances. It is thus a summary of 
one’s access to wealth and opportunities and hence defines one’s social hierarchy (Oakes 
& Rossi 2003).   In the current study, SES was used as a measure of social class position 
(Galobardes et al. 2006; Oakes & Rossi 2003). Using the Oyedeji SES classification, SES 
was derived from a combination of educational attainment and occupation class (Oyedeji 
1985). In case of a child, the mean of four scores (two for the father and two for the 
mother) to the nearest whole number is the social class assigned to the child. I-II: UPPER 
CLASS, III-V: LOWER CLASS 
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Table 1 
Showing Oyedeji social classification scheme 
Social class Profession Educational 
attainment 
I Professional, Senior public servants, owners of 
large business concerns, Senior military 
officers, large scale contractors. 
University graduates 
or equivalents. 
II Non-academic professionals e.g. Nurses, 
Secondary school teachers, secretaries, Owners 
of medium sized business. Intermediate grade 
public servants. 
School certificate 
holders and 
equivalents 
III Non manual skilled works including clerks, 
typists, telephone operators, Junior school 
teachers, Drivers 
Grade II teachers or 
equivalent 
IV Petty traders, Laborers, Messengers Primary School 
certificate 
V Unemployed, Full time housewives, students, 
subsistence farmers 
No formal education 
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Dependent Variables  
The dependent variables were clinical outcomes defined as the presence of any 
death (mortality) or Heart failure events.  
Mortality refers to deaths in the study population. The REMEDY study had used events 
forms to encode deaths either in the hospital or at home (Karthikeyan et al., 2012; Zuhlke 
et al., 2014). In case of any death during the study period, the physician fills a death 
report form using autopsy report for those patients who consented to autopsy, death 
certificate reports or verbal communication of events from the family in the case of 
patients who died at home (Karthikeyan et al., 2012; Zuhlke et al., 2014). The study 
counted all-cause mortality and specific type of mortality e.g. deaths from heart failure, 
rheumatic fever, infective endocarditis etc. This variable was adopted and used in the 
secondary data analysis. 
Heart failure events. All patients recruited into the REMEDY study had a heart failure 
events form filled by each study clinician (Karthikeyan et al., 2012; Zuhlke et al., 2014). 
New onset or repeat heart failure occurring in each patient during the 2 year follow up 
period was reported and encoded into the heart failure events form (Karthikeyan et al., 
2012; Zuhlke et al., 2014). Heart failure was diagnosed if any 2 of the following 3 criteria 
were present: (1) symptoms (dyspnea on exertion or at rest, orthopnea, nocturnal 
paroxysmal dyspnea, or ankle edema) or signs (rales, increased jugular venous pressure, 
or ankle edema) of CHF; (2) radiological signs of pulmonary congestion; and (3) 
treatment with diuretics (Karthikeyan et al., 2012; Zuhlke et al., 2014). This variable was 
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adopted and used in the secondary data analysis (Karthikeyan et al., 2012; Zuhlke et al., 
2014). 
Adherence has been consistently defined as “the extent to which a person’s behavior (in 
terms of taking medications, following diets, or executing lifestyle changes) coincides 
with medical or health advice” (Haynes, Taylor & Sackett 1979, p.1-2). It is thus seen as 
the behavior of the patients or care givers who bear responsibility for ensuring the 
patients visit the nurse for the 4 weekly BZP injection. This is supported by previous 
study done on adherence rates to therapy in chronic disease management (Orrell-Valente 
& Cabana 2008). In the REMEDY study, adherence rate was conceptualized as the 
number of times an individual with RHD received prescribed 4 weekly benzathine 
penicillin (BZP) in the one-year period of study (Karthikeyan et al., 2012; Zuhlke et al., 
2014). It was represented as a ratio (%) between the actual monthly injections and 
expected number of monthly injections in a year (Karthikeyan et al., 2012; Zuhlke et al., 
2014). For the purpose of this study, the same adherence rate was adopted (Zuhlke et al., 
2015).  Thus, the patient actual number of BZP received during the period of observation 
was divided by the total expected number of BZP injections and expressed as a 
percentage ratio (Zuhlke et al., 2015).  
Adherence rate (%) = Number of actual BZP injections received in a year 
   Number of expected BZP injections in a year 
The adherence rate was then coded into one of the following clinically significant ordinal 
categories: low (<35%), medium (36-79%), and high (≥80%) (Karthikeyan et al., 2012; 
Zuhlke et al., 2015). A patient with rheumatic heart disease is expected to receive at least 
80% of the annual prescribed injections (Cannon et al., 2017; Carapetis et al., 2012).  
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When an individual patient receives less than 80% of the injections, they are at a higher 
risk of recurrent ARF and its complications (Cannon et al., 2017; Carapetis et al., 2012). 
For the purpose of this study, benzathine penicillin prophylaxis adherence was classified 
as good (≥80%) and poor (< 80%) adherence rate. 
Covariates. Control variables (covariates) for this study included age, sex, disease 
severity at enrolment, heart failure status at enrolment, NYHA class at enrolment and 
number of months since diagnosis with RHD (Karthikeyan et al., 2012; Zuhlke et al., 
2014). According to Creswell (2009), control variables are a “special type of independent 
variable…because they potentially influence the dependent variable” (p. 51). Age at last 
birthday will be used during data preparation for analysis. Gender and socioeconomic 
status will be measured as categorical variables on a nominal scale. 
Analyses 
 
The IBM Statistical Package for the Social Sciences (SPSS) Statistics 23 (SPSS 
23) was used in the analysis of the data. The IBM SPSS 23 is a systematic tool that helps 
with data evaluation with precise results that allows one to assess all outcomes of interest 
(IBM, 2015). This statistical software is a suitable choice for my data analysis because of 
the availability of descriptive and inferential analysis features suitable for the dataset that 
I used in this study. 
Handling Missing Data 
 
Being a secondary data analysis, missing data can be a challenging problem 
resulting from incomplete data entry giving rise to some data fields having missing 
values (CDC 2010). The dataset was thus evaluated for missing values. Less than 10% of 
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the variables had missing data; thereby providing no need for further adjustments or 
modifications (CDC, 2010). 
Descriptive Statistics 
Socio-demographic characteristics (age, sex, weight, height, educational 
attainment, occupation, and income, clinical characteristics (RHD severity, HF etc) and 
echocardiographic parameters (EF, LVEDD) comparisons between the two cohorts were 
done using descriptive statistics. The difference between the two cohorts was described 
using Student t test for continuous variables such as age, EF and LEVDD and chi square 
for categorical variables such as sex, educational attainment and occupation. 
Analyses method to address each question 
 
Research question (RQ)1: 
Does the number of heart failure events differ between RHD patients of low SES 
and RHD patients of higher SES? 
Null hypothesis (H01): There is no difference in number of heart failure events 
between RHD patients of low SES and RHD patients of higher SES. 
Alternate hypothesis (Ha1): There is a difference in number of heart failure events 
between RHD patients of low SES and RHD patients of higher SES. 
For this study, HF was measured as the number of heart failure events occurring 
among patients with RHD over the two year follow up period (Gordis 2015; Hagenaars 
2018). This is a continuous variable measured as a count or frequency of occurrence of 
repeat HF events in each patient (Gordis 2015; Hagenaars 2018). Poisson regression 
analysis was used to compare the differences between the two cohorts. Poisson regression 
methods was used in assessing the difference in HF events between the two SES 
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groupings. Poison regression analysis was chosen because it is a generalized linear model 
that models count data. The Poisson regression is chosen because of the assumption that 
HF events changes linearly with equal increment, the changes in the, HF events from 
combined effects of different confounders (such as age, gender etc) are multiplicative, 
that at the each level of the covariates the number of cases has variance equal to the mean 
and that the observations are independent. The plots of residuals versus the mean at 
different levels of the predictor variable was used to determine violations of assumption 
or to ascertain whether variances are too large or too small. It is the appropriate statistics 
here because the dependent variable (heart failure) is a count of events occurring over a 
time period. 
Research question (RQ)2: 
 
Does the mortality rate differ between RHD patients of low SES and RHD 
patients of higher SES? 
Null hypothesis (H02): There is no difference in mortality rates between RHD 
patients of low SES and RHD patients of higher SES. 
Alternate hypothesis (Ha2): There is a difference in mortality rates between RHD 
patients of low SES and RHD patients of higher SES. 
Mortality refers to the occurrence of death in a defined population during a specified time 
period (Gordis 2015; Hagenaars 2018). For this study, mortality was measured as the 
number of deaths occurring among patients with RHD over the two year follows up 
period (Gordis 2015; Hagenaars 2018). This is a categorical variable measured on the 
nominal scale (Gordis 2015; Hagenaars 2018). Mortality was measured as present (death) 
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or absent (alive) in the patients with RHD over the two year follows up period. Logistic 
regression analysis was used to compare the mortality rate between the two cohorts. 
Research Question (RQ) 3: 
Is there a significant difference in the number of heart failure events between 
RHD patients of low SES and RHD patients of Higher SES when adjusting for the effect 
of benzathine penicillin prophylaxis adherence? 
Null hypothesis (H03): There is no significant difference in the number of heart 
failure events between RHD patients of low SES and RHD patients of Higher SES after 
adjusting for the effect of benzathine penicillin prophylaxis adherence rates. 
Alternate (HA3): There is a significant difference in the number of heart failure 
events between RHD patients of low SES and RHD patients of Higher SES when 
adjusting for the effect of benzathine penicillin prophylaxis adherence rates. 
In answering Research Question 3, Poisson regression model with mediation 
analysis was used by considering three variables, SES (independent), BZP adherence 
(independent), and heart failure (dependent). I analyzed whether adding BZP adherence 
to the Poisson regression model mediates the relationship between SES and heart failure. 
Poison regression analysis was chosen because it is a generalized linear model that 
models count data like rates. In addition, it was chosen because of the assumption that 
heart failure changes linearly with equal increment, the changes in the number of heart 
failure events from combined effects of different confounders (such as age, gender etc) 
are multiplicative, that at the each level of the covariates the number of cases has 
variance equal to the mean and that the observations are independent. The plots of 
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residuals versus the mean at different levels of the predictor variable was used to 
determine violations of assumption or to ascertain whether variances are too large or too 
small. Using Poisson regression gave me the opportunity to analyze interrelationships 
among multiple risk factors or exposure variables and a single outcome (Sullivan, 2012). 
It is the appropriate statistics here because the dependent variable (heart failure) is a 
count of events occurring over a time period. 
Research question (RQ) 4: 
Is there a significant difference in the risk of dying (mortality) between RHD 
patients of low SES and RHD patients of Higher SES when adjusting for the effect of 
benzathine penicillin prophylaxis adherence? 
Null (H03): There is no significant difference in risk of mortality between RHD 
patients of low SES and RHD patients of Higher SES after adjusting for the effect of 
benzathine penicillin prophylaxis adherence rates. 
Alternate (HA3): There is a significant difference in risk of mortality between 
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect 
of benzathine penicillin prophylaxis adherence rates. 
In answering research question 4, multivariable logistic regression with mediation 
analysis was used by considering three variables, SES (independent), BZP adherence 
(independent), and mortality (dependent). I analyzed whether adding BZP adherence to 
the multivariable logistic regression model mediate the relationship between SES and 
mortality. Stepwise (forward regression) method was used in conducting the regression 
analysis. In addition, statistical significance of the indirect effects of mediation was tested 
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using bootstrapping method (Preacher, & Hayes, 2008). Using Multivariable statistics 
gives me the opportunity to analyze interrelationships among multiple risk factors or 
exposure variables and a single outcome as stated in the analysis for RQ2 (Sullivan, 
2012).  
Threats to Validity 
The data collected from the REMEDY study on patient drug treatment adherence 
is based on the patient’s self-report. Self-reported measures of adherence are a potential 
threat to internal validity because of the tendency to overestimate adherence rates 
(Dunbar-Jacob, Schlenk, & McCall, 2012). Patients (and their care givers in the case of 
minors) in a bid to recall past events may inaccurately recall information about missed 
medication doses (Gordis 2015; Dunbar-Jacob et al., 2012) Socially desirable response 
when questioned by their primary care provider especially that which helps to cast them 
in a good light before their primary care provider is also likely to occur (Gordis 2015; 
Dunbar-Jacob et al., 2012) Recall bias, social desirability bias, and errors in self-
observation may contribute to an overestimation of adherence (Gordis 2015; Dunbar-
Jacob et al., 2012). In addressing these biases, the REMEDY study protocol used 
standard operating procedures with uniform definitions for terms and variables used. In 
addition, patient records and in some cases phone conversation with managing primary 
care physician were used in order to improve the quality of information. 
The REMDY study used symptomatic RHD patients who presented in the 
hospital for treatment. The exclusion of asymptomatic patients might have introduced 
some form of self selection. These patients may thus not be representative of the target 
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population of all patients with RHD considering the fact that access to care and disease 
severity might have played a role in their presentation. However, by ensuring that patient 
recruitment follows the approve research protocol at each site through the use of standard 
operating procedures and definition of terms for all variables and outcomes variables, the 
usability of the findings in the target population of patients with RHD globally was 
enhanced and thus the external validity 
The REMEDY study collected data from patients after obtaining IRB approval 
and protects all information as required in accordance with the HIPPA act. In addition, 
written informed consent was obtained from all participants before and during the entire 
period of study. No patient was denied care nor was care linked to participation in the 
study. Walden University IRB was however sought and obtained for the current study. 
There is no need for a fresh written informed consent from the patients as REMEDY had 
originally informed the patients about the possibility of using their data for future 
publications. The data was anonymized, password protected and electronically 
transmitted from the REMEDY data manger after due permission was obtained from the 
principal investigator.  Access to all data was restricted. After the successful defense of 
this dissertation study, the data will be stored in this manner for 5 years and then 
destroyed subsequently.  
Ethical Considerations 
Deidentified data contained within the Nigerian register of the REMEDY study 
registry for RHD was used. Patient data and information was protected as required by 
federal law section 308 (d) of the Public Health Service Act and the Privacy act of 1974. 
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Walden Institutional Review Board approval (IRB approval number 12-04-19-0550282) 
was obtained before embarking on this study. 
Summary 
In summary, this was a secondary data analysis of a prospectively collected data 
utilizing data from the REMEDY study, a multicenter, international registry of patients 
with RHD seen in 25 facilities spread across 12 African countries, India and Yemen. The 
study was a retrospective cohort study utilizing secondary data analysis of datasets of 
patients with RHD collected in a longitudinal, prospective study in Nigeria. The study 
examined the association between SES and clinical outcomes in patients with RHD seen 
in inpatient, emergency room and outpatient departments of these developing countries. 
In addition, the effect of adherence to benzathine penicillin, a treatment option shown to 
impact outcome in RHD management on the relationship between SES and clinical 
outcomes was assessed.  
The IBM SPSS version 23 was used for all analysis.  Student t test and chi square 
was used in comparing the baseline characteristics of the cohort being evaluated. Poisson 
regression analysis was used to examine the relationship between SES and heart failure 
(RQ1) and also the mediator role of adherence to BZP prophylaxis in the relationship 
between SES and heart failure (RQ3). Multivariable regression was used to assess the 
relationship between SES and mortality rates (RQ2)., and the mediator role of adherence 
to BZP prophylaxis in the relationship between SES and mortality (RQ4). 
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Chapter 4: Results 
Introduction 
The purpose of this secondary data analysis was to assess the relationship between 
individual level SES and clinical outcomes (heart failure events and mortality) in patients 
with RHD as well as examine how adherence to benzathine penicillin prophylaxis 
mediates the effect of socioeconomic status on clinical outcomes (heart failure events and 
mortality rate) for these patients with RHD. Data from 198 symptomatic RHD patients in 
Nigeria were used to address the following research questions and hypotheses: 
RQ1. Does the number of heart failure events differ between RHD patients of low 
SES and RHD patients of higher SES? 
H01: There is no difference in number of heart failure events between RHD 
patients of low SES and RHD patients of higher SES 
HA1: There is a difference in number of heart failure events between RHD 
patients of low SES and RHD patients of higher SES 
RQ2: Does the risk of mortality differ between RHD patients of low SES and 
RHD patients of higher SES? 
H02: There is no difference in risk of mortality between RHD patients of low SES 
and RHD patients of higher SES 
HA2: There is a difference in risk of mortality between RHD patients of low SES 
and RHD patients of higher SES 
RQ3: Is there a significant difference in number of heart failure events between 
RHD patients of low SES and RHD patients of Higher SES when adjusting for the effect 
of benzathine penicillin prophylaxis adherence? 
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H03: There is no significant difference in number of heart failure events between 
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect 
of benzathine penicillin prophylaxis adherence rates. 
HA3: There is a significant difference in number of heart failure events between 
RHD patients of low SES and RHD patients of Higher SES after adjusting for the effect 
of benzathine penicillin prophylaxis adherence rates. 
RQ4: Is there a significant difference in risk of mortality between RHD patients 
of low SES and RHD patients of Higher SES when adjusting for the effect of benzathine 
penicillin prophylaxis adherence? 
H04: There is no significant difference in risk of mortality between RHD patients 
of low SES and RHD patients of Higher SES after adjusting for the effect of benzathine 
penicillin prophylaxis adherence rates. 
HA4: There is a significant difference in risk of mortality between RHD patients 
of low SES and RHD patients of Higher SES after adjusting for the effect of benzathine 
penicillin prophylaxis adherence rates. 
In this chapter, I discuss the results of this study in relation to the research 
questions, hypothesis, sample characteristics, and descriptive analysis used in this study. 
Data Collection 
Secondary data analysis was conducted using de-identified data from the Nigerian 
site of the REMEDY study; a registry based longitudinal study of symptomatic RHD 
patients that collected clinical, sociodemographic, and echocardiographic data from all 
the patients enrolled into the registry using an eleven page questionnaire that is divided 
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into sections for ease of administration at baseline, 12 months and 24 months. These 
patients were categorized into two cohorts based on their SES classification for Nigerian 
and developing settings as proposed by Oyedeji. The study received IRB approval from 
Walden University. 
Descriptive statistics 
Demographic characteristics 
There were 198 RHD patients in the Nigerian register of the REMEDY study. A 
total of 15 (7.6%) of the participants were missing key variables for analysis and so were 
excluded.  
The mean age of the participants was 24.2 years with a standard deviation of 13.9 
years. The median age was 21.1 years; 95% confidence interval (CI) = 8.9 – 53.0 years. 
A total of 110 (60.1%) of the participants were from the low SES group while 73 (39.9%) 
were from the higher SES group (χ2 =3.95, p=0.08). participants 
Table 2 presents data on the demographic and clinical characteristics of the 183 
subjects with RHD that were studied.  The two SES groups were similar in sex 
composition (χ2 =1.50, p = 0.62), and age group distribution (χ2 =2.55, p = 0.13). The 
clinical parameters were also similar for the two groups at baseline. The groups were 
similar in past history of heart failure (χ2 =3.65, p = 0.06), disease severity at baseline (χ2 
=0.07, p=0.86) and BZP prophylaxis adherence at baseline (χ2 =0.98, p = 0.36). 
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Table 2 
Demographic and Clinical Characteristics of 183 Subjects with RHD by SES grouping  
Variable Low SES 
N=110 
Higher SES 
N=73 
Total  
N=183 
 
Socio-demographic n (%) n (%) n (%) p 
Sex      
Female 85(76.6) 46(61.2) 131(71.6) 0.08 
Male 25(23.4) 27(28.8) 52(28.4)  
Age category     
Adult  77(66.4) 40(59.7) 117(63.9) 0.62 
Child 39(33.6) 27(40.3) 66(36.1)  
Clinical Parameters     
Past History of Heart 
failure 
    
Yes 75(67.0) 38(53.5) 113(61.7) 0.06 
No 37(23.0) 33(46.5) 70(38.3)  
Disease Severity     
Mild 85(75.9) 56(78.9) 141(77.0) 0.72 
Severe 27(24.1) 15(21.1) 42(23.0)  
BZP Prophylaxis     
Yes 40(36.4) 33(45.2) 73(39.9) 0.36 
No 70(63.6) 40(54.8) 110(60.1)  
Note. SES= Socioeconomic status 
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 Table 3 presents data on the anthropometric and echocardiography parameters of 
the 183 subjects with RHD that were studied. The two groups were similar in mean 
weight, height and BMI distribution (p=0.72, 0.71 and 0.94 respectively). 
Echocardiography parameters were also comparable between the two groups. Left 
ventricular end diastolic dimensions (LVEDD) was similar (t=0.95, p=0.35), ejection 
fraction (EF) was similar for both groups (t=0.63, p=0.53), fractional shortening (FS) was 
similar as well (t=0.25, p=0.84). 
Table 3 
Comparison of Anthropometric and Echocardiographic Parameters at Baseline by SES 
grouping 
Anthropometric 
Parameters 
Low SES Higher SES 
P value 
          Mean                 SD          Mean SD 
Weight (Kg)               48.3 17.3 49.3 16.6 0.72 
Height (m)             1.52     0.16 1.55 0.16 0.71 
BMI(Kg/m2) 20.0 4.49 20.0 4.71 0.94 
Person years  1.83  0.76 2.01 0.71 0.11 
Echocardiography 
Parameters 
     
LVEDD 55.7 11.5 53.8 13.2 0.35 
EF (%) 55.5 15.5 57.0 15.4 0.53 
FS (%) 30.4 9.8 30.8 8.9 0.84 
Note. EF= Ejection fraction, FS= fractional shortening, LVEDD= left ventricular end 
diastolic dimensions 
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Table 4.  
Comparison of Number of Persons Ever Had Heart Failure by SES grouping 
Variable N Mean SD t p value 
Lower SES 110 10.O 3.1 2.20 0.03 
Higher SES 73 3.0 3.0   
 
Table 4 presents data on number of patients with heart failure in the study. Ten RHD 
patients from lower SES group   ever had heart failure compared with 3 from higher SES 
group (Mean=3.1, p=0.03). 
Table 5 
Comparison of Mean Heart Failure Events by SES grouping 
Variable N Mean Min Max p value 
Lower SES 110 26 18 44 0.05 
Higher SES 73 14 6 22  
 
Table 5 presents data on number of heart failure events in the study. There were 26 heart 
failure events recorded in patients from lower SES group compared with 14 events 
recorded from patients from higher SES group (Mean=3.1, p=0.03). 
Research Question 1: The Relationship between SES and heart failure events 
What is the relationship between socioeconomic status and heart failure events in 
patients with rheumatic heart disease?  The null hypothesis was that there is no difference 
in number of heart failure events between RHD patients of low SES and RHD patients of 
higher SES. The alternate hypothesis is there is a difference in number of heart failure 
events between RHD patients of low SES and RHD patients of higher SES. Heart failure 
events refers to the number of times each patient developed heart failure in the course of 
the 2 years follow up.  Based on descriptive statistics on Research Question 1 variables, 
potential confounders assessed by bivariate statistics are age, person year of follow up 
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and disease severity at baseline.  Poisson regression to compare heart failure events 
before and after adjusting for these potential confounders was conducted. 
Poisson regression. The crude heart failure events (HF) were first calculated for 
the groups before conducting the Poisson regression. Lower SES group RHD patients had 
cumulatively 26 (23.6%) heart failure events compared with their higher SES 
counterparts who had 14 (19.2%) heart failure events (p-0.04, ℵ2 =4.972). Poisson 
regression analysis of heart failure events (dependent variable) on SES groupings 
(independent variable) was performed to compare the difference in heart failure events 
between RHD patients in the lower SES group and RHD patients in the higher SES 
group. I used the grouped data analysis approach and also log-transformed the person-
year variable where it is used as an off-set variable in fitting the Poisson regression 
model. The Poisson regression model is defined in terms of log of expected counts HF as: 
Loge (Y)= β0 + β1X1, where the X represents the explanatory variable (SES). The 
distribution of the count variable (heart failure events) was checked to see if it followed 
Poisson distribution using one sample KS statistics (p=1.00) and descriptive statistics 
(mean count=0.07 variance=0.066). From this, I assumed that heart failure event was 
approximately Poisson distributed since the model had a very strong assumption; that is, 
the mean of the research data was approximately equal to the variance of the data. 
The Poisson model, used in this analysis, fit reasonably well the research data 
because the goodness-of-fit chi-square test was not statistically significant, p = 1.0 (Table 
6). If the test had been statistically significant, it would have indicated that the data did 
not fit the model well. 
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Table 6 
Model Goodness of Fit 
           Value df Sig. 
Likelihood ratio 92.980 166 1.000 
Pearson Chi-Square 828.259 166 1.000 
  
Model parameter estimates include the regression coefficients for each of the 
predictor variables along with p-values and 95% confidence intervals for the coefficients. 
The number of heart failure events among RHD patients was then predicted by the 
exponentiated coefficient, exp (B), or the regression incidence rate ratio. The exp (B) for 
RHD patients in the low SES group was 4.379 while that of the comparison group (higher 
SES) was 1.00. Based on these results, the RHD patients from low SES group would be 
4.8 times more likely to experience heart failure events compared with their counterparts 
from a higher SES group (Table 7). This was significant (p=0.04).  
 
Table 7 
Poisson Regression Analysis of Heart Failure Events on SES Group  
Parameter B SE 
Hypothesis Test 
OR 
95% CI for OR 
Wald   p Lower Upper 
(Intercept) -5.769 .7071 66.560  0.00 .003 .001 .012 
Lower SES  1.563 .7638 4.186  0.04 4.771 1.068 21.318 
Dependent Variable: Heart failure rate, Model: (Intercept), SES, offset = person year 
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Considering the above findings, I will thus reject the Null Hypothesis 1 since 
heart failure was found to be significantly associated with lower SES compared with 
higher SES grouping. 
Research Question 2: The Relationship Between SES and Mortality Rate 
Bivariate Analyses 
Before constructing the model for multivariable logistic analyses, I conducted 
bivariate statistics (chi square) using cross tabulations to examine the potential 
confounders across the independent variable and dependent variables. Disease severity at 
baseline and BZP adherence rates were significantly associated with mortality. 
Logistic Regression Analyses 
I used binomial logistic regression to analyze the relationship between SES 
grouping and mortality. All the variables included in the model are categorical. Mortality 
was coded as 0 if it did not occur and 1 if it occurred. For this logistic regression, death 
(mortality occurring) was the dependent variable. SES was grouped to low SES group 
and higher SES group. For this logistic regression, lower SES was the reference group. 
Eight participants were dropped from the initial analysis due to missing data resulting in a 
sample of 190 participants. From my initial analysis, of all the potential confounders, 
only diseases severity and BZP adherence were significantly associated with the 
dependent and independent variables. In the final model, only 15 participants were 
dropped because of missing variables leaving 183 participants in the analyses. The 
parameter estimates from the logistic regression model showed that the odds of dying 
(mortality) is approximately 42% lower for RHD patients in the lower SES group 
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compared to RHD patients in the higher SES group (OR=0.58; 95% CI 0.26- 1.29). The 
result is not statistically significant because the 95% confidence interval does include 1 
and p = 0.18.  I will thus not reject the Null hypothesis. Therefore, there is no statistically 
significant association between SES and mortality in RHD patients aged 5 to 60 years 
seen in Nigeria (Table 8). 
Table 8 
Logistic Regression Model Coefficients of SES with Mortality 
 
Variable OR 95% CI 
 LL                   UL 
P 
Intercept 0.48   0.19 
Lower SES 0.58 0.26 1.29 0.18 
 
Research Question 3: The Relationship Between SES and Number of Heart Failure 
Events When Considering the Possible Effect of Adherence to Benzathine Penicillin 
(BZP) Prophylaxis 
In mediation analysis, the three main effects of interest are the (a) total effect, (b) 
direct effect, and (c) indirect or mediation effect of exposure on outcome (Mascha, 
Dalton, Kurz, & Saager, 2013). SES grouping is the exposure, and number of heart 
failure event is the outcome. I examined adherence to BZP prophylaxis as a mediator of 
SES and number of heart failure events. The total effect of SES on heart failure events 
does not adjust for adherence to BZP prophylaxis. According to Mascha,Dalton, Kurz, 
and Saager (2013), the total effect of an exposure on an outcome includes adjustment for 
confounding variables but ignores the specified mediator. Using Poisson regression as in 
RQ1, the total effect of SES on heart failure events after adjusting for age and disease 
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severity as confounders was first calculated. SES group 1(low SES group) was found to 
be 4.8 times more likely to develop heart failure events compared with SES group 2 
(higher SES group) with person years of follow up as the offset variable (OR = 4.77, 95% 
CI [1.07, 21.32]). Next, the effect of BZP adherence on heart failure events was 
calculated.  Poor BZP adherence was 58% more likely to develop a heart failure event 
compared with those with good BZP adherence (OR = 0.42, 95% CI [0.12, 1.45]). 
Subsequently, the effect of SES on heart failure events with BZP adherence in the model 
with age and disease severity as confounders (covariates) and person years of follow up 
as offset variable was calculated. Table 9 displays the final model coefficients after 
including the mediator variable (adherence to BZP prophylaxis). Lower SES was 
associated with a 4.6 times likelihood of developing heart failure event compared with 
those in higher SES (OR = 4.57, 95% CI [1.02, 20.43]. The effect of the mediator 
variable, BZP prophylaxis is also shown. Patients with good BZP adherence were 55% 
less likely to develop heart failure event compared with those with poor BZP adherence 
(OR=0.45, 95% CI [0.12, 1.58, p=0.21). 
75 
 
Table 9 
Poisson Regression Model Coefficients of SES on Heart Failure with Adherence as a 
Mediator 
 
Parameter B SE 
Hypothesis Test 
OR 
95% CI for OR 
Wald   p Lower Upper 
(Intercept) -5.495 .7261 57.278  0.00 0.004 .001 .017 
Lower SES  1.519 .6598 3.949  0.04 4.567 1.021 20.43 
Good 
Adherence 
-.809 .6518 1.540  0.22 0.445 0.12 1.598 
Dependent Variable: Heart failure events, Model: (Intercept), SES, offset = person year 
SE=Standard error, CI=confidence interval, OR=Odds ratio, LL=lower limit, UL=upper 
limit 
 
In order to prove mediation, the mediator variable must affect the outcome 
variable independent of the exposure variable (Mascha et al., 2013). Adherence to BZP 
prophylaxis was not significantly associated with heart failure events independent of SES 
as the p-value is 0.22. However, the relationship between SES and heart failure remains 
significant even though the effect size (OR) is slightly less than that without the mediator 
variable (4.77 vs 4.56). This shows partial mediation and so the null hypothesis is thus 
rejected. Adherence partially mediate the relationship between SES and heart failure 
events. Therefore, adherence to BZP partially mediates the effect of SES on the odds of 
developing heart failure events in patients with RHD contained within the Nigerian 
registry of REMEDY. 
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Research Question 4: The Relationship Between SES and Mortality Rate When 
Considering the Possible Effect of Adherence to Benzathine Penicillin (BZP) 
Prophylaxis 
As seen in research question 3, for mediation analysis, the three main effects of 
interest are the (a) total effect, (b) direct effect, and (c) indirect or mediation effect of 
exposure on outcome (Mascha, Dalton, Kurz, & Saager, 2013). SES grouping is the 
exposure, mortality rate is the outcome. I examined adherence to BZP prophylaxis as a 
mediator of SES and mortality.  
The total effect of SES on mortality does not adjust for adherence to BZP prophylaxis. 
According to Mascha,Dalton, Kurz, and Saager (2013), the total effect of an exposure on 
an outcome includes adjustment for confounding variables but ignores the specified 
mediator. The total effect of SES on mortality after adjusting for confounders was first 
calculated.  Here, SES group 1(low SES group) was found to be 62 % less likely to 
develop mortality compared with SES group 2 (higher SES group) when the potential 
confounders (age category, sex, person years of follow up, disease severity at baseline) 
were adjusted for in the logistic regression model (OR = 0.38, 95% CI [0.04,4.09]. 
The direct effect of SES on incident heart failure rate which is the effect that is 
independent of adherence to BZP prophylaxis was then calculated next. Table 10 displays 
the final model coefficients after including the mediator variable (adherence to BZP 
prophylaxis). Here, SES group 1(low SES group) is now about 48.8% likely to die when 
mediator is added to the binomial logistic regression model (OR=0.51, 95% CI =0.04 -
7.03). The effect of the mediator variable, BZP prophylaxis is also shown. Poor 
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adherence is 3.28 times more likely to be associated with mortality compared with good 
adherence (OR=3.28. 95% CI=0.42. 25.78. p=0.26) 
Table 10 
Logistic Regression Model Coefficients of SES with Mortality and Adherence as a 
Mediator 
Variable B OR 95% CI 
   LL              UL 
P 
value 
Intercept -13.599    0.001 
Poor adherence 1.19 3.28 0.42 25.78 0.26 
Severe RHD 1.47 4.35 0.32 59.17 0.27 
Lower SES -.67 0.51 0.04 7.03 0.62 
Age ≥18 years 2.06 7.83 0.47 130.72 0.15 
Female  1.86 6.42 0.37 112.84 0.20 
Person year 6.54 694.24 26.38 18270.36 <0.001 
      
SE=Standard error, CI=confidence interval, OR=Odds ratio, LL= lower limits, UL= 
upper limits SES= Socioeconomic class, RHD=rheumatic heart disease 
 
In order to prove mediation, the mediator variable must affect the outcome 
variable independent of the exposure variable (Mascha et al., 2013). Adherence to BZP 
prophylaxis was not significantly associated with mortality independent of SES as the p-
value is 0.073. However, the person year of follow up was significantly associated with 
mortality as the p value is <0.001. (Table 10). The null hypothesis is thus not rejected. 
Adherence does not mediate the relationship between SES and mortality. 
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Summary 
This chapter presented the results of regression analyses to examine the 
relationship between SES and clinical outcomes (mortality and heart failure events) in 
symptomatic RHD patients in Nigeria. The Null hypothesis for research question 1 was 
rejected because heart failure events was found to be significantly associated with lower 
SES compared with higher SES grouping. In the same vein, I rejected the Null hypothesis 
for research question 3 because adherence to BZP partially mediates the effect of SES on 
heart failure events in the patients with RHD. However Null hypothesis for research 
questions 2 and 4 were not rejected. For research question 2, mortality was not found to 
be significantly associated with lower SES compared with higher SES grouping. For 
research question 4, adherence to BZP did not significantly mediate the relationship 
between SES and mortality.  
In the next chapter I will discuss the study results in relation to previous research 
related to disparities in clinical outcomes in symptomatic patients with RHD and the use 
of benzathine penicillin prophylaxis in the long-term management of these patients. 
Limitations and recommendations for future research will be provided along with 
implications for social change. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this secondary database analysis study was to assess the 
relationship between individual level SES and clinical outcomes (number of heart failure 
events and mortality rate) in patients with RHD contained within the Nigerian Registry of 
the REMEDY Study. In addition, this study examined how adherence to benzathine 
penicillin prophylaxis mediate the effect of socioeconomic status on clinical outcomes 
(number of heart failure events and mortality rate) for these patients with RHD. The 
health lifestyle theory is an important but underdeveloped area of theoretical discourse 
related to medical sociology and public health (Cockerham 2005; 2013).  This theory 
places emphasis on how structural variables such as socioeconomic status, age, gender, 
and race/ethnicity, social networks and living conditions provide the social context for 
socialization and experience that ultimately determine lifestyle dispositions and practices 
(Cockerham 2005;2013). Poisson regression was used for answering question 1 and 
question 3 while logistic regression analysis was used for research questions 2 and 4. 
Poisson regression is a generalized linear model form of regression analysis used to 
model count data and contingency tables (Field 2015).  Poisson regression assumes the 
response variable (dependent variable) has a Poisson distribution (Field 2015). It also 
assumes the logarithm of the expected value of the response variable can be modelled by 
a linear combination of unknown parameters (Field 2015). In contrast logistic regression 
is a binary form of classification and represents outcomes that are dichotomous. the 
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logistic regression estimates the probability of getting one of the two possible outcomes 
(Field 2015)  
  In this chapter, the discussions will be centered on findings relating to prior 
theoretical and empirical literature, theory application, interpretations of findings, 
limitations, recommendations, implications for this study, and conclusions. 
Research question 1 examined whether the number of heart failure events differ 
between RHD patients of low SES and RHD patients of higher SES. When answering 
Research Question 1 using the Poison regression model generated, RHD patients from 
lower SES group were 4.8 times more likely to develop heart failure events in the two 
year follow up period compared with their counterparts in the higher SES group (p=0.04). 
This effect was significant at p=0.04 leading to my rejection of the Null hypothesis. 
Rejecting the Null hypothesis means that there is enough evidence to say that SES alone 
can predict the frequency of heart failure events in these RHD patients. This is to say that 
difference in SES groupings have a significant influence on which RHD patient develop 
subsequent heart failure events. The findings of an increased  risk of heart failure events 
in RHD patients from lower SES compared with those from higher SES in this current 
study is in tandem with what Zuhlke et al. (2016) reported using country level 
socioeconomic groupings rather than individual level SES to assess disparities in heart 
failure incidences and mortality among symptomatic RHD patients in Africa, Yemen and 
India (Zuhlke et al., 2016).  It is also in tandem with the findings of Burch  et al., (2016) 
who studied the effect of SES on viral suppression among HIV infected individuals and 
reported that low SES significantly predict viral non suppression (adjusted hazard ratio 
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[HR] for greatest financial hardship vs none 2·3, 95% CI 1·4–3·9; non-employment 3·0, 
2·1–4·2; unstable housing vs home-owner 3·3, 1·8–6·1; non-university education 1·6, 
1·1–2·3 ) (Burch et al., 2016). While clinical outcomes for chronic diseases are hinged 
more on behavior and social support in the community, a person’s SES group may define 
their company, the type of community they live in and also by extension their code of 
conduct and possibly health seeking behavior (Cockerham et al., 2017). Unlike HIV 
where family and peer support exist to assist and improve patient adherence to therapy, 
RHD is a neglected disease of poverty usually associated with abandonment and poor 
access to care (Cockerham et al., 2017). Lower SES as seen here is usually associated 
with low purchasing power (Cockerham et al., 2017). In situations where health 
expenditure is majorly out of pocket as subsist in Nigeria, treatment cost may be 
prohibitively high leading to non-adherence to drug therapy and hence recurrent heart 
failure events as seen among these RHD patients from lower SES group (Cockerham et 
al., 2017). Other factors inherent in the community like social capital available, 
healthcare access may also play important role in addition to SES in determining 
outcome for patients with RHD and thus provide avenues for future research (Cockerham 
et al., 2017). 
 The fact that those in lower SES were about 4.8 times more likely to develop 
heart failure events is of clinical relevance in the management of patients with RHD from 
lower SES household (Cockerham et al., 2017). SES determines purchasing power in 
Nigeria and by extension access to healthcare (Uzochukwu et al., 2015). Lower SES is 
associated with low purchasing power and by extension inability to pay for healthcare 
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services especially when the payment is out-of-pocket (Uzochukwu et al., 2015). The 
implication for these patients is possible increased exposure to recurrent heart failure and 
its attendant consequences as a result of inability to pay for healthcare services thus 
affecting outcome for them (Cockerham et al., 2017; Uzochukwu et al., 2015; Zuhlke et 
al., 2016).  
Research Question 3 examined whether there is a significant difference in number 
of heart failure events between RHD patients of low SES and RHD patients of higher 
SES when adjusting for the effect of benzathine penicillin prophylaxis adherence. In 
answering research question 3 Poisson regression model was used to assess the potential 
mediatory role of adherence to BZP prophylaxis in the relationship between SES and 
number of heart failure events in these RHD patients. The results of the Poisson 
regression analysis showed that the odds of developing heart failure event were 
approximately 4.8 times more likely for patients of lower SES group compared to RHD 
patients in the higher SES group when excluding adherence to BZP prophylaxis but 
holding disease severity and age group of participant constant. (OR = 4.77, 95% CI [1.07, 
21.32]). Similarly, being an RHD patients with poor adherence to BZP prophylaxis was 
associated with a 58% likelihood of developing a heart failure event compared with those 
RHD patients from higher SES (OR = 0.42, 95% CI [0.12, 1.45], p = 0.21). When finally, 
BZP adherence was added to the model with SES as predictors of heart failure events, 
SES remain significant as a predictor of heart failure events even though the odds 
reduced to 4.6 while BZP adherence was non-significant in predicting heart failure event. 
This thus means that BZP adherence partially mediates the relationship between SES and 
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heart failure leading to my rejection of the Null hypothesis (Field, 2015). Adherence to 
BZP has been shown to be an important determinant of heart failure recurrences in 
patients with RHD (Watkins et al., 2017; Zuhlke et al., 2016). My findings here are in 
tandem with what Okello reported among Ugandan children with RHD where increased 
incidence of heart failure was seen in children who had poor adherence to BZP 
prophylaxis (Okello et al., 2017). However, the fact that the result showed partial 
mediation suggest that some other variables apart from BZP adherence might be 
influencing the odds of heart failure in these patients with RHD. Adult age which was 
associated with a significant increased risk of heart failure events in a separate model 
assessing confounders maybe one of such variables acting alongside BZP adherence to 
influence the relationship between SES and heart failure events (Watkins et al., 2017). 
Adult age may be a proxy for the duration lived with the disease especially since the 
disease usually begins in childhood (Gitura 2016; Okello et al., 2017; Watkins et al., 
2017). Research has shown that RHD disease profile and outcomes worsened as the 
patient gets older (Gitura 2016; Okello et al., 2017). This is important in the sense that 
such persons would have lived longer with the disease especially seeing that the disease 
commonly starts in mid childhood (Claussen, 2015; Cockerham et al., 2017;  Zühlke et 
al., 2015). In addition, being older increases the chances of having a more severe disease 
in addition to developing other complications such as arrhythmias and infective 
endocarditis all of which increases the risk of recurrent heart failure (Claussen, 2015; 
Cockerham et al., 2017;  Zühlke et al., 2015). It is thus not surprising to find increased 
number of heart failure events, a usual complication of RHD in those older than 18 years 
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(Gitura 2016; Okello et al., 2017). While BZP adherence has been demonstrated to 
improve clinical outcomes especially heart failure and ARF, this is however only useful 
early on in the disease before permanent geometric changes occur in the heart (Gitura 
2016; Okello et al., 2017). Therefore, our findings of partial mediatory influence of BZP 
prophylaxis in this cohort of mixed population of adult and children may point to the 
need to disaggregate future study by age groups (Gitura 2016; Okello et al., 2017; 
Watkins et al., 2017). This was why person year of follow up was also added as an offset 
variable in the model (Field 2015). Therefore, while SES alone may be one factor that 
significantly predispose to heart failure in RHD patients studied in Nigeria, however, 
when SES is combined with the age of the patient, disease severity and years of follow-
up, it may become an even more important determining factor for the possible risk of 
heart failure in patients with RHD as shown in this study (Claussen, 2015; Cockerham et 
al., 2017;  Zühlke et al., 2015). 
Research Question 2 examined whether the risk of mortality differ between RHD 
patients of low SES and RHD patients of higher SES. When answering research question 
2 using simple logistic regression model, RHD patients from lower SES group were 
about 42% less likely to die in the two year follow up period compared with their 
counterparts in the higher SES group (OR=0.58, 95% CI=0.26 -1.29, p = 0.18). Because 
this was not statistically significant at p = 0.05, the Null hypothesis was not rejected. 
Failing to reject the Null hypothesis means that there is not enough evidence to say that 
SES alone can predict mortality in these RHD patients (Field, 2013). In other words, the 
difference in SES groupings have no significant influence on the risk of death among 
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these cohort of RHD patient (Field 2013). While data is lacking for all-cause mortality by 
socioeconomic quintiles for patients with RHD, Zuhlke et al., (2016) in the REMEDY 
study had evaluated 3343 RHD patients across 14 developing countries (Zuhlke et al., 
2016). They reported a median age at death of 28 years. Similar to my findings in the 
current study, Zuhlke et al., also reported a significant increase in mortality with 
increasing age, with adults having a 50% higher risk of death than those <18 years of age 
(HR, 1.50; 95% CI, 1.11–1.95) (Zuhlke et al., 2016). Even though individual level SES 
was not assessed in their study, most of the deaths they reported was found in patients 
from   low-income countries (21%) compared with those from middle-income countries 
(12% to 17%) (Zuhlke et al., 2016). The association of higher SES with increased risk of 
death in my study, though not significantly so raises important questions for management 
of patients with RHD. While lower socioeconomic status has been associated with an 
increased risk of death in patients with stroke and ischaemic heart disease, the finding of 
the reverse here needs further studies for clarification (Psaltopoulou et al., 2017). 
Research question 4 examined whether there is a significant difference in risk of 
mortality between RHD patients of low SES and RHD patients of higher SES when 
adjusting for the effect of benzathine penicillin prophylaxis adherence. In answering 
research question 4 multivariable logistic regression model was used to assess the 
potential mediatory role of adherence to BZP prophylaxis in the relationship between 
SES and risk of mortality in these RHD patients. In this logistic regression analysis, the 
odds of dying were approximately 49% less likely for patients of lower SES group 
compared to RHD patients in the higher SES group when adherence to BZP was 
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excluded in the model but holding disease severity and adherence to BZP prophylaxis 
constant. (OR=0.51; 95% CI 0.04- 7.03).   However, when adherence to BZP prophylaxis 
was included in the model, the odds of dying in RHD patients from lower SES group was 
48.8% lower compared with RHD patients from higher SES group (OR=0.51, 95% CI 
=0.04 -7.03). In addition, the odds of dying for those RHD patients with poor adherence 
(<80% total expected dose of BZP per year) was about 3.3 time more compared with 
those RHD patients with good adherence (>80% of total expected dose of BZP per year) 
albeit not statistically significant (OR=3.2 8, 95% CI=0.42-25.78, p= 0.26). Our finding 
is similar to the report by Okello et al. (2017) where Ugandan RHD patients with poor 
BZP adherence had significantly greater mortality (31% vs. 9%, log rank p < 0.001) and 
also significantly higher risk of death compared with those with good adherence 
(HR = 3.81, CI 1.92–7.63, p = 0.001) (Okello et al., 2017).  Death in those with poor 
adherence was also significantly associated with heart failure (HR 8.36, CI 3.28–21.31, 
p = 0.001) (Okello et al., 2017).   
Thus, SES alone unlike the model for heart failure events is inadequate in 
explaining the risk of dying in patients with RHD. However, when other factors like 
disease severity, the age of the patient and also the duration of follow up are considered 
in the model, SES may have a significantly important determining factor for the possible 
risk of dying in patients with RHD. The longer an RHD patient lives with the chronic 
disease, the more likely other complications like stroke and arrhythmias set in and 
thereby increasing the risk of dying.  Older patients as seen in this study would have lived 
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longer with the disease especially seeing that the disease commonly starts in mid 
childhood.   
Impact of Key Variables on Multiple Outcomes in RHD  
RHD is a chronic disease associated with multiple outcomes (Cannon et a., 2017; 
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Several key variables like disease 
severity at diagnosis, left ventricular end diastolic dimension, presence of arrhythmias, 
adherence to drug therapy and presence of complications such as endocarditis, stroke and 
acute rheumatic fever will have a significant impact on the eventual outcome of the 
patient (Watkins et al., 2017). Cannon et al., (2017) using a disease register had reported 
that a diagnosis of severe RHD especially in young persons is associated with a 10% 
chance of dead within 6 years of diagnosis (Cannon et al., 2017). They further reported 
that patients diagnosed with moderate RHD had a mixed prognosis 10 years after 
diagnosis with roughly one third progressing to severe RHD (with or without surgery), 
one third remained moderate, and one third regressing to mild RHD (Cannon et al., 
2017). Those who had mild RHD at diagnosis had the most favorable prognosis, with 
over 60% remaining mild after 10 years, and 10% being inactive by the end of the 14‐
year study period (Cannon et al., 2017). 
RHD being a disease of poverty and social disadvantage is associated with poor 
access to healthcare with consequent increase episodes of unrecognized acute rheumatic 
heart fever (ARF) ( Watkins et al., 2017). Recurrent ARF episodes cause severe damage 
to the valve structure as well as also predisposing the patients to dilatation of heart 
chambers and other severe consequences (Cannon et a., 2017; Chamberlain-Salaun et al., 
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2016; Zuhlke et al., 2016). BZP secondary prophylaxis is used to prevent such 
recurrences and hence improve outcomes in RHD patients (Cannon et a., 2017; 
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016).  Furthermore, there was no 
significant association of poor adherence to BZP prophylaxis with the occurrence of heart 
failure events in our study. However, I found adherence to BZP to partially mediate the 
influence of SES on heart failure events confirming what has been reported in the 
literature (Cannon et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016).Such 
effect of  BZP prophylaxis is thought to be greatest in early stages of the disease (Cannon 
et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Our patients like many 
others in developing countries access medical care late when their disease is severe with 
associated substantial valve damage from unrecognized recurrent rheumatic fever 
episodes at which point the hemodynamic consequences of severe valve disease may be 
the overwhelming determinants of prognosis (Cannon et a., 2017; Chamberlain-Salaun et 
al., 2016; Zuhlke et al., 2016). It is thus not surprising that adherence to BZP prophylaxis 
did not significantly affect the clinical outcome (Heart failure and death) in Nigerian 
patients with RHD (Cannon et a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 
2016). 
Even though RHD begins in childhood, its highest burden is seen in adolescents 
and young adults living in poverty and social disadvantage (Cannon et a., 2017; 
Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Disease severity at diagnosis and 
the degree of adherence to benzathine penicillin prophylaxis are the most important risk 
factors to heart failure recurrence in RHD patients (Cannon et a., 2017; Chamberlain-
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Salaun et al., 2016; Zuhlke et al., 2016). Complications such as heart failure and death are 
usually associated with severe disease at diagnosis, poor access to BZP prophylaxis as 
well as poor adherence to BZP prophylaxis when available (Chamberlain-Salaun et al., 
2016; Zuhlke et al., 2016). Together with recurrent heart failure, these factors contribute 
to the increased mortality rates seen in people with RHD (Cannon et a., 2017; Zuhlke et 
al., 2016). Low SES which is the surrogate for poverty affects access to care, BZP 
prophylaxis and other treatments for complications like heart failure thereby increasing 
the risk of dying in such patients (Cannon et a., 2017; Chamberlain-Salaun et al., 2016; 
Zuhlke et al., 2016). 
Interpretation of Findings 
This study and others on RHD patients contained within the REMEDY global 
registry adds to the findings of the relationship between SES and the significant increases 
in number of heart failure events (Zuhlke et al. 2014; Zuhlke et al., 2016). Similarly, it 
also adds to the findings on the relationship of SES and risk of mortality in symptomatic 
RHD patients contained within the REMEDY global registry (Zuhlke et al., 2014; 2016).   
The Health lifestyle theory used in this study offered an opportunity for 
understanding how class circumstance (socioeconomic status) influences patients’ 
choices and decision (agency) on adhering to the monthly penicillin injection 
(adherence), a health behavior necessary for improving the clinical outcome for these 
symptomatic patients with RHD (Cockerham 2005;2013).  
 An increased risk of heart failure among patients from lower SES was observed in 
my study similar to what was reported by Zuhlke et al., in the REMEDY study though 
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Zuhlke et al., used country level SES classification by the World Bank in grouping the 
patients (Zuhlke et al., 2016).  Lower SES is associated with worsening clinical outcomes 
in chronic disease such as RHD (Baro et al., 2018). Our finding is also similar to what 
Potter et al., (2019) reported in a review of the literature where they showed a significant 
association between incident heart failure with SES households (Potter et al., 2019). 
Potter reported that patients from low SES households have a 1.62 times risk of heart 
failure compared with those from higher SES households (HR 1.62, 95% CI 1.50-1.76) 
(Potter et al., 2019). Furthermore, my study observed adherence to BZP prophylaxis in 
patients with RHD only partially mediate the relationship between SES and frequent 
heart failure events. Okello et al., had demonstrated a reduced incidence of heart failure 
among Ugandan RHD patients with good adherence to BZP (Okello et al., 2017). Even 
though my study did show a partial influence of BZP adherence on heart failure events, 
however, the fact that other researchers too have shown an association between poor 
adherence to BZP prophylaxis and increased risk of heart failure events calls for a closer 
follow up of RHD patients with lower SES in order to help reduce the frequency of heart 
failure events and thus  improve their outcomes (Cannon et a., 2017; Watkins et al., 
2017). 
A reduced risk of death among patients from low SES, though not statistically 
significant, was also found in this study in contrast to what Okello et al., reported among 
RHD patients in Uganda (Okello et al., 2017). Furthermore, this study also found poor 
adherence to benzathine penicillin prophylaxis to be associated with an increased risk of 
mortality though this did not reach statistical significance.  This lack of significance may 
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be related to the mixed population of children and adults used in this study (Cannon et a., 
2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016). Children being products of a 
household SES are a different population from adults. It will thus be advisable that future 
study should try to separate the two groups and assess their effects separately (Cannon et 
a., 2017; Chamberlain-Salaun et al., 2016; Zuhlke et al., 2016).  
Limitations of the Study 
This study was based on secondary data analysis of data contained within the 
Nigerian site of the REMEDY study. The sample in this study consisted of symptomatic 
RHD patients presenting for care in a hospital emergency room, ward or clinic and may 
not be representative of all RHD patients in those localities and thus may limit 
generalizability of the results of the study to all populations of patients with RHD. As for 
the sampled population, the use of a mixed population consisting of both children and 
adults with RHD in the study might introduce some complexities in the effect of SES on 
the studied outcomes. SES for an adult is a direct reflection of the person’s social 
standing, economic class and ability to access and possibly pay for services especially 
health services in Nigeria which is mainly out of pocket expense. However, for a child, 
the SES classification used was the parental SES classification.  Even though this was 
done because child care is a responsibility of the parents and care givers, it may however 
over estimate or under estimate the effect of SES especially since parental care is not so 
much dependent on SES but culture in Africa (Amzat & Razum 2018).  However, in 
future, children should be separated from adults and if possible, compared on the key 
outcomes variables so as to be able to make appropriate age specific conclusions seeing 
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that the disease characteristics may differ between children and adults. Other variables 
such as duration lived with the diseases, frequency of hospitalization and total household 
income all factors that have been shown to significantly impact outcome in chronic 
disease management could have been assessed if available in the data set. But this was 
not possible because of their unavailability in the dataset. 
Implications for Social Change 
Rheumatic heart disease (RHD) has continued to significantly contribute to 
morbidity and mortality among children and adolescents in resource constraint 
communities especially in sub Saharan Africa where poverty and poor hygiene continues 
to plague the vast majority of the population (Marijon et al., 2012; Zühlke & Steer 2013) 
It is important to assess how SES, age category and adherence to BZP impacts on 
clinical outcomes for chronic diseases such as rheumatic heart diseases especially in 
developing countries where health expenditure is mainly out of pocket expenses 
(Remond et al., 2016; Yacoub et al., 2016; Zühlke et al., 2016). Understanding the 
mechanism through which SES and adherence to BZP prophylaxis affects these health 
outcomes represent potentially modifiable targets for intervention to improve health 
outcomes not just for patients with RHD but also for patients with other chronic diseases 
(Remond et al., 2016; Yacoub et al., 2016; Zühlke et al., 2016). 
In this study, risk for developing heart failure events was higher for RHD patients 
in low SES group compared with those in higher SES group. Finding a significantly 
higher number of heart failure events in patients from low SES in this study points to the 
need to pay close attention to the management of these group of patients with RHD 
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especially as it relates to counseling on those factors that may predispose to the frequent 
recurrence of heart failure (Classen 2015; Cockerham et ail., 2017). Thus, physicians, 
cardiologists and nurses who care for these patients will need to do more in counseling 
about drug adherence especially adherence to diuretics for heart failure and also 
benzathine penicillin for prevention of recurrent rheumatic fever, an important cause of 
heart failure in RHD patients (Gonzalez et al., 2016). In addition, health policy will need 
to focus on reducing barriers to care for people in the low SES groupings of the society as 
well as reducing out of pocket expense to health care by making health insurance and 
social services universally accessible. This will help improve clinical outcomes for 
patients with RHD and other chronic diseases. 
Recommendations 
This secondary analysis study was conducted on de-identified data sets of 
symptomatic RHD patients in Nigeria collected using case record forms by cardiologists 
working in multiple hospitals sites from January 2010 to January 2014. The major 
limitation of this study of being a secondary data analysis is acknowledged. However, 
larger prospective longitudinal studies utilizing multiple sites in Nigeria are needed to 
confirm the findings of this study. 
Previous studies had utilized a mixed population consisting of children and adults 
just as was done in this study. Future researchers should focus on disaggregating the 
children data from the adult data in order to make definitive statements about SES and its 
effects on clinical outcomes such as heart failure and mortality in patients with RHD. 
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SES grouping utilized proxies such as educational attainment and occupation 
rather than actual income earned by the patients (or parents of children). Since care in 
Nigeria is mainly out of pocket expenses, it is important that future researchers try to 
assess actual income or earnings of the patients as a measure of SES.  In addition, a 
prospective cohort design would be most appropriate for such future research. 
Recommendation for practice as a result of this study includes the need for 
increased surveillance and monitoring for adherence to management in patients with 
RHD from social disadvantaged backgrounds in order to improve their clinical outcomes. 
Conclusions 
RHD is a disease of social disadvantage associated with poverty, malnutrition, 
poor hygiene and sanitation, overcrowding and poor access to health. The persistence of 
these poverty defining problems in Nigeria and most parts of sub Saharan Africa is what 
is currently responsible for the persistence of RHD as well as the deaths occurring from 
the complications of the disease.   
The results of this study showed that after controlling for age, disease severity at 
baseline and adherence to BZP, symptomatic RHD patients from the Nigerian sites of the 
REMEDY study who are from low SES group have a higher incidence heart failure rates 
compared with their counterparts from a higher SES group. Poor adherence to BZP 
prophylaxis did show partial mediation of the relationship between SES and number of 
heart failure events or but not mortality. Furthermore, lower SES was significantly 
associated with increased risk for developing heart failure events. These findings suggest 
that socioeconomic gradient is an important predictor of clinical outcomes (heart failure 
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events) among symptomatic RHD patients seen in Nigeria.  Paying attention to 
socioeconomic status of a patient can be an important tool for improving clinical 
outcomes for these patients.  Future research should examine the effect of socioeconomic 
status and clinical outcomes for patients with RHD separately for children and adults. 
This will help bring about results that can be used for targeted actions and policy 
formulation and implementation appropriate for each age group. 
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